<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="794291a5-d481-4cfe-9dbb-2d1391bb68d5"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS safely and effectively. See full prescribing information for </content>
      <content styleCode="bold">METHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE TABLETS</content>
      <content styleCode="bold">.<br/>
         <br/>
      </content>
      <content styleCode="bold">METHYLPHENIDATE HYDROCHLORIDE extended-release tablets, for oral use,Â </content>
      <content styleCode="bold">CII<br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 2000</content>
   </title>
   <effectiveTime value="20240402"/>
   <setId root="85ef422d-af27-4126-9841-6892af1871d6"/>
   <versionNumber value="29"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119723554" root="1.3.6.1.4.1.519.1"/>
            <name>Actavis Pharma, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="e6715a7e-40de-4fa6-95e8-c0932cd57a2b"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240521"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="62037-725" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methylphenidate Hydrochloride</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylphenidate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="18"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5KY68S2577" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="62037-725-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076772" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">725</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>capsule shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="62037-734" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methylphenidate Hydrochloride</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylphenidate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="27"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5KY68S2577" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="4AQJ3LG584" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2--ALUMINUM LAKE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="62037-734-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076772" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48324" displayName="gray" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">734</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>capsule shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="62037-726" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methylphenidate Hydrochloride</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylphenidate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="36"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5KY68S2577" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="62037-726-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076772" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">726</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>capsule shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="62037-727" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Methylphenidate Hydrochloride</name>
                        <formCode code="C42930" displayName="TABLET, FILM COATED, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Methylphenidate Hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="54"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="4B3SC438HI" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPHENIDATE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="207ZZ9QZ49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METHYLPHENIDATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="88XHZ13131" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FUMARIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B1QE5P712K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2208 (100 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="36SFW2JZ0W" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (15 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>LACTOSE MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="74G4R6TH13" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:1)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5KY68S2577" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHACRYLIC ACID - METHYL METHACRYLATE COPOLYMER (1:2)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8Z96QXD6UM" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIETHYL CITRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="G2M7P15E5P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 3350</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="532B59J990" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYVINYL ALCOHOL, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="100"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="62037-727-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20190304"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA076655" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20190304"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48675" displayName="CII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" displayName="red" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>brown</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">727</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>capsule shaped</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="12" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_b8247d6c-6c5c-42e6-87fb-88109999e00f">
               <id root="283f879f-c801-493b-961c-c7cd6ac83a45"/>
               <code code="34066-1" codeSystem="2.16.840.1.113883.6.1" displayName="BOXED WARNING SECTION"/>
               <title>WARNING: ABUSE, MISUSE, AND ADDICTION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">Methylphenidate hydrochloride extended-release tablets has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride extended-release tablets, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <content styleCode="xmChange">Before prescribing methylphenidate hydrochloride extended-release tablets, assess each patientâs risk for abuse, misuse, and addiction. Educate patients and their families about these risks, proper storage of the drug, and proper disposal of any unused drug. Throughout methylphenidate hydrochloride extended-release tablets treatment, reassess each patientâs risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>) and Drug Abuse and Dependence (<linkHtml href="#LINK_2de45e7d-f3d8-47ab-8e03-328793cd40b6">9.2</linkHtml>)].</content>
                        </content>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">WARNING: ABUSE, MISUSE, AND ADDICTION</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">See full prescribing information for complete boxed warning.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Methylphenidate hydrochloride extended-release tablets has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride extended-release tablets, can result in overdose and death (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>, <linkHtml href="#LINK_2de45e7d-f3d8-47ab-8e03-328793cd40b6">9.2</linkHtml>, <linkHtml href="#LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">10</linkHtml>):</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="bold">Before prescribing methylphenidate hydrochloride extended-release tablets, assess each patientâs risk for abuse, misuse, and addiction.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Educate patients and their families about these risks, proper storage ofÂ </content>
                              <content styleCode="bold">the drug, and proper disposal of any unused drug.</content>
                           </item>
                           <item>
                              <content styleCode="bold">Throughout treatment, reassess each patientâs risk and frequentlyÂ </content>
                              <content styleCode="bold">monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                           </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_a5e4bc18-b499-4f8d-b82c-6f782e8670d9">
               <id root="9d589da8-68e9-4170-aea1-1e33b7d6a14d"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <title/>
               <text/>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Boxed WarningÂ  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 10/2023</paragraph>
                        <paragraph>Indications and Usage (<linkHtml href="#LINK_3cb08e9a-c626-4f09-826b-a31c30d657f0">1</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â 10/2023</paragraph>
                        <paragraph>Dosage and Administration (<linkHtml href="#LINK_59089a5a-d30b-469d-bd81-fe040c9fe821">2.1</linkHtml>, <linkHtml href="#LINK_cfb03ed7-bf05-4032-8ff0-72a057e486d2">2.6</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  10/2023</paragraph>
                        <paragraph>Dosage and Administration, Maintenance/Extended Treatment (<linkHtml href="#LINK_1bb532a1-fed7-403a-9f45-612783b07785">2.5</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  RemovedÂ  Â  Â  Â  Â  10/2023Â  Â  Â  Â  Â  Â  Â  Â  Â Â </paragraph>
                        <paragraph>Contraindications (<linkHtml href="#LINK_7e878866-735f-4bef-9638-ba9f34c1a9ed">4</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  10/2023</paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>, <linkHtml href="#LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">5.2</linkHtml>, <linkHtml href="#LINK_b92519ff-9458-421f-81b3-fca364a4324a">5.3</linkHtml>, <linkHtml href="#LINK_a28c27a6-3d0e-4f69-ab45-c0027b8ab91f">5.4</linkHtml>, <linkHtml href="#LINK_d388e15d-cc41-40cc-8a5c-c38d753b1d61">5.6</linkHtml>, <linkHtml href="#LINK_febf9dbb-ae80-4603-95ec-d2aa0a45abec">5.7</linkHtml>, <linkHtml href="#LINK_0ab0a071-a25b-48a1-8e57-b285bf2d93b3">5.8</linkHtml>, <linkHtml href="#LINK_7d1f546e-e064-47fa-aaa6-2cac7d83c207">5.11</linkHtml>, <linkHtml href="#LINK_b669de13-880c-40bc-992e-0f9f4362dbc8">5.12</linkHtml>, <linkHtml href="#LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">5.13</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  10/2023Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â Â </paragraph>
                        <paragraph>Warnings and Precautions (<linkHtml href="#LINK_febf9dbb-ae80-4603-95ec-d2aa0a45abec">5.7</linkHtml>)Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  RemovedÂ  Â  Â  Â  Â 10/2023</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_3cb08e9a-c626-4f09-826b-a31c30d657f0">
               <id root="67f21cae-23f3-46db-a0c6-16d8646a4457"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 <content styleCode="italics">[see Clinical Studies (<linkHtml href="#LINK_5d531aa6-fdc9-4f38-8464-038d25aaadb5">14</linkHtml>)]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tabletsÂ are a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65.Â (<linkHtml href="#LINK_39ab309b-5251-4db5-bc8d-48eb03db2c7a">1</linkHtml>) </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_d61016be-ec2e-4b16-9e42-025c99ec7905">
               <id root="81680ad3-8655-465c-a51d-3fcde3957712"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Methylphenidate hydrochloride extended-release tablets should be taken once daily in the morning and swallowed whole with the aid of liquids. Methylphenidate hydrochloride extended-release tablets should not be chewed or crushed. Methylphenidate hydrochloride extended-release tablets Â may be taken with or without food. (<linkHtml href="#LINK_73452f46-2843-440e-89cd-4dab5457c1b4">2.2</linkHtml>) </item>
                           <item>For children and adolescents new to methylphenidate, the recommended starting dosage is 18 mg once daily. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 54 mg/day in children and 72 mg/day in adolescents. (<linkHtml href="#LINK_d4f0dca7-c2d7-4f41-8fbe-3ac4f20c997f">2.3</linkHtml>) </item>
                           <item>For adult patients new to methylphenidate, the recommended starting dose is 18 or 36 mg/day. Dosage may be increased by 18 mg/day at weekly intervals and should not exceed 72 mg/day for adults. (<linkHtml href="#LINK_d4f0dca7-c2d7-4f41-8fbe-3ac4f20c997f">2.3</linkHtml>)</item>
                           <item>For patients currently using methylphenidate, dosing is based on current dose regimen and clinical judgment. (<linkHtml href="#LINK_618d3897-4e68-41f3-9650-9aa29138d106">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_59089a5a-d30b-469d-bd81-fe040c9fe821">
                     <id root="0c5fe919-b080-4346-a370-641bc711f9d6"/>
                     <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
                     <title>2.1 Pretreatment Screening</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Prior to treating patients with methylphenidate hydrochloride extended-release tablets, assess:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>
                              <content styleCode="xmChange">for the presence of cardiac disease (i.e., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam)Â <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">5.2</linkHtml>)].</content>
                              </content>
                           </item>
                           <item>
                              <content styleCode="xmChange">the family history and clinically evaluate patients for motor or verbal tics or Touretteâs syndrome before initiating methylphenidate hydrochloride extended-release tablets<content styleCode="italics">Â [see Warnings and Precautions (<linkHtml href="#LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">5.13</linkHtml>)].</content>
                              </content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_73452f46-2843-440e-89cd-4dab5457c1b4">
                     <id root="f20312ee-fe5d-4d26-bed9-c3492550addb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets should be administered orally once daily in the morning with or without food.</paragraph>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets must be swallowed whole with the aid of liquids, and must not be chewed, divided, or crushed <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#LINK_829fb2dd-301c-42bd-9162-8a069c60d4d2">17</linkHtml>)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d4f0dca7-c2d7-4f41-8fbe-3ac4f20c997f">
                     <id root="6f850090-145b-4e3d-a9e3-466bb8b6e900"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Patients New to Methylphenidate</title>
                     <text>
                        <paragraph>The recommended starting dose of methylphenidate hydrochloride extended-release tablets for patients who are not currently taking methylphenidate or stimulants other than methylphenidate is 18 mg once daily for children and adolescents and 18 or 36 mg once daily for adultsÂ (see Table 1). </paragraph>
                        <table width="1000px">
                           <caption>Table 1. Methylphenidate Hydrochloride Extended-Release Tablets Recommended Starting Doses and Dose Ranges</caption>
                           <col width="33.33%"/>
                           <col width="33.33%"/>
                           <col width="33.33%"/>
                           <tbody>
                              <tr>
                                 <td valign="top" styleCode=" Toprule">Â <content styleCode="bold">Patient Age</content>
                                 </td>
                                 <td valign="top" styleCode=" Toprule">Â <content styleCode="bold">Recommended Starting Dose</content>
                                 </td>
                                 <td valign="top" styleCode=" Toprule">Â <content styleCode="bold">Dose Range</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Toprule">Â Children 6-12 years of age </td>
                                 <td valign="top" styleCode=" Toprule">Â 18 mg/day </td>
                                 <td valign="top" styleCode=" Toprule">Â 18 mg - 54 mg/day </td>
                              </tr>
                              <tr>
                                 <td valign="top">Â Adolescents 13-17 years of age </td>
                                 <td valign="top">Â 18 mg/day </td>
                                 <td valign="top">Â 18 mg - 72 mg/day not to exceed 2 mg/kg/day </td>
                              </tr>
                              <tr>
                                 <td valign="top">Â Adults 18-65 years of age</td>
                                 <td valign="top">Â 18 or 36 mg/day</td>
                                 <td valign="top">Â 18 mg - 72 mg/day</td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_618d3897-4e68-41f3-9650-9aa29138d106">
                     <id root="63aefded-bde4-4a0c-bcfd-9e4e8bc45188"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Patients Currently Using Methylphenidate</title>
                     <text>
                        <paragraph>The recommended dose of methylphenidate hydrochloride extended-release tablets for patients who are currently taking methylphenidate twice daily or three times daily at doses of 10 to 60 mg/day is provided in Table 2. Dosing recommendations are based on current dose regimen and clinical judgment. Conversion dosage should not exceed 72 mg daily. </paragraph>
                        <table width="900px">
                           <caption>Table 2. Recommended Dose Conversion from Methylphenidate Regimens to Methylphenidate Hydrochloride Extended-Release Tablets</caption>
                           <col width="56.3%"/>
                           <col width="43.7%"/>
                           <tbody>
                              <tr>
                                 <td valign="bottom" styleCode=" Toprule">Â <content styleCode="bold">Previous Methylphenidate Daily Dose</content>
                                 </td>
                                 <td valign="top" styleCode=" Toprule">
                                    <content styleCode="bold">Recommended MethylphenidateÂ Hydrochloride <br/>
            Extended-ReleaseÂ Tablets <br/>
            Starting Dose</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td valign="top" styleCode=" Toprule">Â 5 mg Methylphenidate twice daily or three times daily </td>
                                 <td valign="top" styleCode=" Toprule">Â 18 mg every morning </td>
                              </tr>
                              <tr>
                                 <td valign="top">Â 10 mg Methylphenidate twice daily or three times daily </td>
                                 <td valign="top">Â 36 mg every morning </td>
                              </tr>
                              <tr>
                                 <td valign="top">Â 15 mg Methylphenidate twice daily or three times daily </td>
                                 <td valign="top">Â 54 mg every morning </td>
                              </tr>
                              <tr>
                                 <td valign="top">Â 20 mg Methylphenidate twice daily or three times daily </td>
                                 <td valign="top">Â 72 mg every morning </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Other methylphenidate regimens: Clinical judgment should be used when selecting the starting dose. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1bb532a1-fed7-403a-9f45-612783b07785">
                     <id root="136182d2-e3a3-43ed-a968-1580595c8c6d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Dose Titration</title>
                     <text>
                        <paragraph>Doses may be increased in 18 mg increments at weekly intervals for patients who have not achieved an optimal response at a lower dose. Daily dosages above 54 mg in children and 72 mg in adolescents have not been studied and are not recommended. Daily dosages above 72 mg in adults are not recommended.</paragraph>
                        <paragraph>A 27 mg dosage strength is available for physicians who wish to prescribe between the 18 mg and 36 mg dosages. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cfb03ed7-bf05-4032-8ff0-72a057e486d2">
                     <id root="8e8ac1e0-02c7-44bb-b3da-52e077540093"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.6 Dosage Reduction and Discontinuation</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">If paradoxical aggravation of symptoms or other adverse reactions occur, reduce dosage or, if necessary, discontinue methylphenidate hydrochloride extended-release tablets.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">If improvement is not observed after appropriate dosage adjustment over a one-month period, discontinue methylphenidate hydrochloride extended-release tablets.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0a25396b-6092-4efc-9641-ce93102fefbd">
               <id root="e3e15b13-b5e7-45a7-bdd1-848fbda655ac"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride extended-release tablets, USP are available in the following dosage strengths: </paragraph>
                  <paragraph>18 mg â Each yellow, film-coated, capsule shaped tablet imprinted with the Andrx logo and 725 on one side and plain on the other side contains 18 mg methylphenidate hydrochloride, USP. </paragraph>
                  <paragraph>27 mg â Each gray, film-coated, capsule shaped tablet imprinted with the Andrx logo and 734 on one side and plain on the other side contains 27 mg methylphenidate hydrochloride, USP. </paragraph>
                  <paragraph>36 mg â Each white, film-coated, capsule shaped tablet imprinted with the Andrx logo and 726 on one side and plain on the other side contains 36 mg methylphenidate hydrochloride, USP. </paragraph>
                  <paragraph>54 mg â Each red brown, film-coated, capsule shaped tablet imprinted with the Andrx logo and 727 on one side and plain on the other side contains 54 mg methylphenidate hydrochloride, USP. </paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 18 mg, 27 mg, 36 mg, and 54 mg (<linkHtml href="#LINK_024fec2d-e702-4356-b5da-059c547d02fb">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_7e878866-735f-4bef-9638-ba9f34c1a9ed">
               <id root="462ab2ab-e825-4e5b-a85a-4d579fefb74b"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text/>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Known hypersensitivity to the product (<linkHtml href="#LINK_5b5caca8-14e3-47e1-864e-621215c1d46c">4.1</linkHtml>)
    </item>
                           <item>Do not use methylphenidate hydrochloride extended-release tablets in patients currently using or within 2 weeks of using an MAO inhibitor (<linkHtml href="#LINK_a0b20943-1499-4cdd-938c-8c1d4d12ac47">4.2</linkHtml>)
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_31e44a17-d68a-49e0-bdc5-70662f27d7fe">
                     <id root="ee5319a6-7065-4e36-be24-634a6e2b35ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">4.1 Hypersensitivity to Methylphenidate</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Hypersensitivity reactions, such as angioedema and anaphylactic reactions, have been observed in patients treated with methylphenidate hydrochloride extended-release tablets. Therefore, methylphenidate hydrochloride extended-release tablets are contraindicated in patients known to be hypersensitive to methylphenidate or other components of the product <content styleCode="italics">[see Adverse Reactions (6.5)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a0b20943-1499-4cdd-938c-8c1d4d12ac47">
                     <id root="1f4281c2-9a18-419a-a348-96d3aec11fee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">4.2 Monoamine Oxidase Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Methylphenidate hydrochloride extended-release tablets are contraindicated during treatment with monoamine oxidase (MAO) inhibitors, and also within a minimum of 14 days following discontinuation of a MAO inhibitor (hypertensive crises may result) <content styleCode="italics">[see Drug Interactions (<linkHtml href="#LINK_692e5a7a-6cf6-43e0-8890-91730c1d1aba">7.1</linkHtml>)]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2b511345-6c60-4f35-b7a7-6dd3c63af0fc">
               <id root="fdeb80fe-a4fd-4ae3-acf5-caba814dcf5c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Risks to Patients with Serious Cardiac Disease: Avoid in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmias, coronary artery disease, or other serious cardiac disease. (<linkHtml href="#LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">5.2</linkHtml>)</item>
                           <item>Increase in Blood Pressure and Heart Rate: Monitor blood pressure and pulse. (<linkHtml href="#LINK_b92519ff-9458-421f-81b3-fca364a4324a">5.3</linkHtml>)</item>
                           <item>Psychiatric Adverse Reactions: Prior to initiating methylphenidate hydrochloride extended-release tablets, screen patients for risk factors for developing a manic episode. If new psychotic or manic symptoms occur, consider discontinuing methylphenidate hydrochloride extended-release tablets. (<linkHtml href="#LINK_a28c27a6-3d0e-4f69-ab45-c0027b8ab91f">5.4</linkHtml>)</item>
                           <item>Seizures: Stimulants may lower the convulsive threshold. Discontinue in the presence of seizures. (<linkHtml href="#LINK_94610366-9b33-4c3e-a264-d03ae2fe6bcf">5.5</linkHtml>) </item>
                           <item>Priapism: If abnormally sustained or frequent and painful erections occur, patients should seek immediate medical attention (<linkHtml href="#LINK_d388e15d-cc41-40cc-8a5c-c38d753b1d61">5.6</linkHtml>) </item>
                           <item>Peripheral Vasculopathy, including Raynaudâs Phenomenon: Careful observation for digital changes is necessary during methylphenidate hydrochloride extended-release tablets treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for patients who develop signs or symptoms of peripheral vasculopathy (<linkHtml href="#LINK_febf9dbb-ae80-4603-95ec-d2aa0a45abec">5.7</linkHtml>) </item>
                           <item>Long-Term Suppression of Growth in Pediatric Patients Closely monitor growth (height and weight) in pediatric patients. Pediatric patients not growing or gaining height or weight as expected may need to have their treatment interrupted. (<linkHtml href="#LINK_0ab0a071-a25b-48a1-8e57-b285bf2d93b3">5.8</linkHtml>) </item>
                           <item>Gastrointestinal obstruction with preexisting GI narrowing. (<linkHtml href="#LINK_fb0580be-0895-4f64-8fec-bf0a1ef266fc">5.9</linkHtml>) </item>
                           <item>Hematologic monitoring: Periodic CBC, differential, and platelet counts are advised during prolonged therapy. (<linkHtml href="#LINK_2f1a655e-45d9-40ae-ab0c-73e22fd66518">5.10</linkHtml>)</item>
                           <item>Acute Angle Closure Glaucoma: Methylphenidate hydrochloride extended-release tablets -treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist. (<linkHtml href="#LINK_7d1f546e-e064-47fa-aaa6-2cac7d83c207">5.11</linkHtml>)</item>
                           <item>Increased Intraocular Pressure and Glaucoma: Prescribe methylphenidate hydrochloride extended-release tablets to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor patients with a history of increased IOP or open angle glaucoma. (<linkHtml href="#LINK_b669de13-880c-40bc-992e-0f9f4362dbc8">5.12</linkHtml>)</item>
                           <item>Motor and Verbal Tics, and Worsening of Touretteâs Syndrome: Before initiating methylphenidate hydrochloride extended-release tablets, assess the family history and clinically evaluate patients for tics or Touretteâs syndrome. Regularly monitor patients for the emergence or worsening of tics or Touretteâs syndrome. Discontinue treatment if clinically appropriate. (<linkHtml href="#LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">5.13</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">
                     <id root="46bfec3c-cbac-47c5-bb37-a99f2d787c9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.1 Abuse,
Misuse, and Addiction</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Methylphenidate hydrochloride extended-release tablets has a high potential for abuse and misuse. The use of methylphenidate hydrochloride extended-release tablets exposes individuals to the risks of abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Methylphenidate hydrochloride extended-release tablets can be diverted for non-medical use into illicit channels or distributionÂ <content styleCode="italics">[see Drug Abuse and Dependence (<linkHtml href="#LINK_2de45e7d-f3d8-47ab-8e03-328793cd40b6">9.2</linkHtml>)].</content>Â Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride extended-release tablets, can result in overdose and deathÂ <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">10</linkHtml>)],</content>Â and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Before prescribing methylphenidate hydrochloride extended-release tablets, assess each patientâs risk for abuse, misuse, and addiction. Educate patients and their families about these risks and proper disposal of any unused drug. Advise patients to store methylphenidate hydrochloride extended-release tablets in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride extended-release tablets to anyone else. Throughout methylphenidate hydrochloride extended-release tablets treatment, reassess each patientâs risk of abuse, misuse, and addiction and frequently monitor for signs and symptoms of abuse, misuse, and addiction.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">
                     <id root="8a72b6b0-9544-4172-ae77-e5495e783370"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.2 Risks to Patients with Serious Cardiac
Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Sudden death has been reported in patients with structural cardiac abnormalities or other serious cardiac disease who were treated with CNS stimulants at the recommended ADHD dosage.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Avoid methylphenidate hydrochloride extended-release tablets use in patients with known structural cardiac abnormalities, cardiomyopathy, serious cardiac arrhythmia, coronary artery disease, or other serious cardiac disease.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b92519ff-9458-421f-81b3-fca364a4324a">
                     <id root="502f623c-922d-4623-a42d-14b8aab58a39"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.3 Increased Blood Pressure and Heart Rate</content>
                     </title>
                     <text>
                        <paragraph>CNS stimulants may cause an increase in blood pressure (mean increase approximately 2 to 4 mmHg) and heart rate (mean increase approximately 3 to 6 bpm). Some patients may have larger increases.</paragraph>
                        <paragraph>Monitor all methylphenidate hydrochloride extended-release tablets-treated patients for hypertension and tachycardia.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a28c27a6-3d0e-4f69-ab45-c0027b8ab91f">
                     <id root="0c78b18a-c234-4303-a994-8e235cba51ae"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.4
Psychiatric Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange underline">Exacerbation of Pre-existing Psychosis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants may exacerbate symptoms of behavior disturbance and thought disorder in patients with a pre-existing psychotic disorder.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange underline">Induction of a Manic Episode in Patients with Bipolar Disorder</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants may induce a manic or mixed episode in patients. Prior to initiating methylphenidate hydrochloride extended-release tablets treatment, screen patients for risk factors for developing a manic episode (e.g., comorbid or history of depressive symptoms or a family history of suicide, bipolar disorder, or depression).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange underline">New Psychotic or Manic Symptoms</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, at the recommended dosage, may cause psychotic or manic symptoms (e.g., hallucinations, delusional thinking, or mania) in patients without a prior history of psychotic illness or mania. In a pooled analysis of multiple short-term, placebo-controlled studies of CNS stimulants, psychotic or manic symptoms occurred in approximately 0.1% of CNS stimulant-treated patients, compared with 0% of placebo-treated patients. If such symptoms occur, consider discontinuing methylphenidate hydrochloride extended-release tablets.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_94610366-9b33-4c3e-a264-d03ae2fe6bcf">
                     <id root="a000c379-df3d-42d9-8539-aabfa79574d7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5
Seizures</title>
                     <text>
                        <paragraph>There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d388e15d-cc41-40cc-8a5c-c38d753b1d61">
                     <id root="ab72ddd0-f18d-4662-a78e-55bb5bb838ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6Â Priapism</title>
                     <text>
                        <content styleCode="xmChange">Prolonged and painful erections, sometimes requiring surgical intervention, have been reported with methylphenidate use in both adult and pediatric male patientsÂ <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_efd2892f-c22f-4333-afee-a38a424fc274">6.5</linkHtml>)].</content>Â Although priapism was not reported with methylphenidate initiation, it developed after some time on Â methylphenidate, often subsequent to an increase in dosage. Priapism also occurred during methylphenidate withdrawal (drug holidays or during discontinuation). Methylphenidate hydrochloride extended-release tablets-treated patients who develop abnormally sustained or frequent and painful erections should seek immediate medical attention.</content>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_febf9dbb-ae80-4603-95ec-d2aa0a45abec">
                     <id root="7ab98db1-0f21-4748-ad21-762d0d4b08d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7Â Peripheral Vasculopathy, including Raynaudâs
Phenomenon</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, including methylphenidate hydrochloride extended-release, used to treat ADHD are associated with peripheral vasculopathy, including Raynaudâs phenomenon. Signs and symptoms are usually intermittent and mild; however, sequelae have included digital ulceration and/or soft tissue breakdown. Effects of peripheral vasculopathy, including Raynaudâs phenomenon, were observed in postmarketing reports and at the therapeutic dosages of CNS stimulants in all age groups throughout the course of treatment. Signs and symptoms generally improved after dosage reduction or discontinuation of the CNS stimulant. </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Careful observation for digital changes is necessary during methylphenidate hydrochloride extended-release tablets treatment. Further clinical evaluation (e.g., rheumatology referral) may be appropriate for methylphenidate hydrochloride extended-release tablets-treated patients who develop signs or symptoms of peripheral vasculopathy.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0ab0a071-a25b-48a1-8e57-b285bf2d93b3">
                     <id root="fe4e57f2-02a4-4e6d-a073-727b7f78ea92"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8
Long-Term Suppression of Growth in Pediatric Patients</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants have been associated with weight loss and slowing of growth rate in pediatric patients.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Careful follow-up of weight and height in children ages 7 to 10 years who were randomized to either methylphenidate or nonmedication treatment groups over 14 months, as well as in naturalistic subgroups of newly methylphenidate-treated and nonmedication-treated children over 36 months (to the ages of 10 to 13 years), suggests that pediatric patients who received methylphenidate for 7 days per week throughout the year had a temporary slowing in growth rate (on average, a total of about 2 cm less growth in height and 2.7 kg less growth in weight over 3 years), without evidence of growth rebound during this development period. Closely monitor growth (weight and height) in methylphenidate hydrochloride extended-release tablets-treated pediatric patients. Pediatric patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_fb0580be-0895-4f64-8fec-bf0a1ef266fc">
                     <id root="44d1b3ba-31b2-496a-8729-af389bf55ec9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9
Potential for Gastrointestinal Obstruction</title>
                     <text>
                        <paragraph>Because the methylphenidate hydrochloride extended-release tablets are nondeformable and does not appreciably change in shape in the GI tract, methylphenidate hydrochloride extended-release tablets should not ordinarily be administered to patients with preexisting severe gastrointestinal narrowing (pathologic or iatrogenic, for example: esophageal motility disorders, small bowel inflammatory disease, âshort gutâ syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckelâs diverticulum). There have been rare reports of obstructive symptoms in patients with known strictures in association with the ingestion of drugs in nondeformable controlled-release formulations. Due to the controlled-release design of the tablet, methylphenidate hydrochloride extended-release tablets should be used only in patients who are able to swallow the tablet whole <content styleCode="italics">[see Patient Counseling Information (<linkHtml href="#LINK_829fb2dd-301c-42bd-9162-8a069c60d4d2">17</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2f1a655e-45d9-40ae-ab0c-73e22fd66518">
                     <id root="7bc6cd47-62d3-4cf1-80b3-870ca7d6dd3f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10
Hematologic Monitoring</title>
                     <text>
                        <paragraph>Periodic CBC, differential, and platelet counts are advised during prolonged therapy. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7d1f546e-e064-47fa-aaa6-2cac7d83c207">
                     <id root="8ad91264-80bf-499a-8d08-133fba54bf2f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.11 Acute Angle Closure Glaucoma</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">There have been rare reports of angle closure glaucoma associated with methylphenidate treatment.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Although the mechanism is not clear, methylphenidate hydrochloride extended-release tablets-treated patients considered at risk for acute angle closure glaucoma (e.g., patients with significant hyperopia) should be evaluated by an ophthalmologist</content>.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b669de13-880c-40bc-992e-0f9f4362dbc8">
                     <id root="8041d69f-bf42-428b-acf8-6fae313ade36"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.12 Increased Intraocular Pressure and Glaucoma</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">There have been reports of an elevation of intraocular pressure (IOP) associated with methylphenidate treatment <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_efd2892f-c22f-4333-afee-a38a424fc274">6.5</linkHtml>)].</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Prescribe methylphenidate hydrochloride extended-release tablets to patients with open-angle glaucoma or abnormally increased IOP only if the benefit of treatment is considered to outweigh the risk. Closely monitor methylphenidate hydrochloride extended-release tablets-treated patients with a history of abnormally increased IOP or open angle glaucoma.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">
                     <id root="b8369960-a960-4656-ba01-efa1177d22eb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="xmChange">5.13 Motor and Verbal Tics, and Worsening of Touretteâs
Syndrome</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">CNS stimulants, including methylphenidate, have been associated with the onset or exacerbation of motor and verbal tics <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_a4768ce1-0ab5-44d4-8bec-6ebf9315eae0">6.2</linkHtml>, <linkHtml href="#LINK_efd2892f-c22f-4333-afee-a38a424fc274">6.5</linkHtml>)]</content>. Worsening of Touretteâs syndrome has also been reported<content styleCode="italics">.</content>
                           </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Before initiating methylphenidate hydrochloride extended-release tablets, assess the family history and clinically evaluate patients for tics or Touretteâs syndrome. Regularly monitor methylphenidate hydrochloride extended-release tablets-treated patients for the emergence or worsening of tics or Touretteâs syndrome, and discontinue treatment if clinically appropriate.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_71e73bdc-d016-45fc-ba98-9bef46ca7b23">
               <id root="31614dbf-337b-4894-abfc-b03fdd2575ea"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disk">
                     <item>Abuse, Misuse, and Addiction <content styleCode="italics">[see Boxed Warning, Warnings and Precautions (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>)]</content>
                     </item>
                     <item>Hypersensitivity to Methylphenidate <content styleCode="italics">[see Contraindications (<linkHtml href="#LINK_31e44a17-d68a-49e0-bdc5-70662f27d7fe">4.1</linkHtml>)]</content>
                     </item>
                     <item>Monoamine Oxidase Inhibitors <content styleCode="italics">[see Contraindications (<linkHtml href="#LINK_a0b20943-1499-4cdd-938c-8c1d4d12ac47">4.2</linkHtml>) and Drug Interactions (<linkHtml href="#LINK_a2e7e795-e2d9-4edc-beff-0d1d2b7e5d2c">7.1</linkHtml>)]</content>
                     </item>
                     <item>Risks to Patients with Serious Cardiac Disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">5.2</linkHtml>)]</content>
                     </item>
                     <item>Increased Blood Pressure and Heart Rate <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b92519ff-9458-421f-81b3-fca364a4324a">5.3</linkHtml>)]</content>
                     </item>
                     <item>Psychiatric Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_a28c27a6-3d0e-4f69-ab45-c0027b8ab91f">5.4</linkHtml>)]</content>
                     </item>
                     <item>Seizures <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_94610366-9b33-4c3e-a264-d03ae2fe6bcf">5.5</linkHtml>)]</content>
                     </item>
                     <item>Priapism <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_d388e15d-cc41-40cc-8a5c-c38d753b1d61">5.6</linkHtml>)]</content>
                     </item>
                     <item>Peripheral Vasculopathy, including Raynaudâs Phenomenon <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_febf9dbb-ae80-4603-95ec-d2aa0a45abec">5.7</linkHtml>)] </content>
                     </item>
                     <item>Long-Term Suppression of Growth in Pediatric Patients<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#LINK_0ab0a071-a25b-48a1-8e57-b285bf2d93b3">5.8</linkHtml>)]</content>
                     </item>
                     <item>Potential for Gastrointestinal Obstruction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_fb0580be-0895-4f64-8fec-bf0a1ef266fc">5.9</linkHtml>)]</content>
                     </item>
                     <item>Hematologic Monitoring <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2f1a655e-45d9-40ae-ab0c-73e22fd66518">5.10</linkHtml>)]</content>
                     </item>
                     <item>Acute Angle Closure Glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_7d1f546e-e064-47fa-aaa6-2cac7d83c207">5.11</linkHtml>)]</content>
                     </item>
                     <item>Increased Intraocular Pressure and Glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b669de13-880c-40bc-992e-0f9f4362dbc8">5.12</linkHtml>)]</content>
                     </item>
                     <item>Motor and Verbal Tics, and Worsening of Touretteâs Syndrome <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">5.13</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph>The most common adverse reaction in double-blind clinical trials (&gt;5%) in pediatric patients (children and adolescents) was abdominal pain upper. The most common adverse reactions in double-blind clinical trials (&gt;5%) in adult patients were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_05f120e0-d64d-400b-ba9b-93ba0f0ed44a">6.1</linkHtml>)]</content>. </paragraph>
                  <paragraph>The most common adverse reactions associated with discontinuation (â¥1%) from either pediatric or adult clinical trials were anxiety, irritability, insomnia, and blood pressure increased <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#LINK_e6f86842-f9b9-4131-80a3-65a10a6712f8">6.3</linkHtml>)]</content>. </paragraph>
                  <paragraph>The development program for methylphenidate hydrochloride extended-release tablets included exposures in a total of 3906 participants in clinical trials. Children, adolescents, and adults with ADHD were evaluated in 6 controlled clinical studies and 11 open-label clinical studies (see Table 3). </paragraph>
                  <paragraph>Safety was assessed by collecting adverse events, vital signs, weights, and ECGs, and by performing physical examinations and laboratory analyses. </paragraph>
                  <table width="800px" cellpadding="4">
                     <caption>Table 3. Methylphenidate Hydrochloride Extended-Release Tablets Exposure in Double-Blind and Open-Label Clinical Studies</caption>
                     <col width="42.16%"/>
                     <col width="18.53%"/>
                     <col width="39.3%"/>
                     <tbody>
                        <tr>
                           <td valign="bottom" styleCode=" Toprule">Â <content styleCode="bold">Patient Population</content>
                           </td>
                           <td valign="bottom" styleCode=" Toprule">Â <content styleCode="bold">N</content>
                           </td>
                           <td valign="bottom" styleCode=" Toprule">Â <content styleCode="bold">Dose Range</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Toprule">Â Children </td>
                           <td styleCode=" Toprule">Â 2216 </td>
                           <td styleCode=" Toprule">Â 18 to 54 mg once daily </td>
                        </tr>
                        <tr>
                           <td>Â Adolescents </td>
                           <td>Â 502 </td>
                           <td>Â 18 to 72 mg once daily </td>
                        </tr>
                        <tr>
                           <td>Â Adults </td>
                           <td>Â 1188</td>
                           <td>Â 18 to 108 mg once daily </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using their own terminology. Consequently, to provide a meaningful estimate of the proportion of individuals experiencing adverse events, events were grouped in standardized categories using MedDRA terminology. </paragraph>
                  <paragraph>The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatment-emergent adverse event of the type listed. An event was considered treatment-emergent if it occurred for the first time or worsened while receiving therapy following baseline evaluation. </paragraph>
                  <paragraph>Throughout this section, adverse reactions are reported. Adverse reactions are adverse events that were considered to be reasonably associated with the use of methylphenidate hydrochloride extended-release based on the comprehensive assessment of the available adverse event information. A causal association for methylphenidate hydrochloride extended-release often cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.</paragraph>
                  <paragraph>The majority of adverse reactions were mild to moderate in severity. </paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reaction in double-blind clinical trials (&gt;5%) in children and adolescents was abdominal pain upper. The most common adverse reactions in double-blind clinical trials (&gt;5%) in adult patients were decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, and hyperhidrosis. (<linkHtml href="#LINK_05f120e0-d64d-400b-ba9b-93ba0f0ed44a">6.1</linkHtml> and <linkHtml href="#LINK_2bc9718e-3c81-4fc8-b2dd-43c0469001b4">6.2</linkHtml>) </paragraph>
                        <paragraph>The most common adverse reactions associated with discontinuation (â¥1%) from either pediatric or adult clinical trials were anxiety, irritability, insomnia, and blood pressure increased. (<linkHtml href="#LINK_e6f86842-f9b9-4131-80a3-65a10a6712f8">6.3</linkHtml>) <br/>Â Â Â  </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva at </content>
                           <content styleCode="bold">1-888-838-2872 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_5c332767-f605-40a5-820b-595282eab85f">
                     <id root="13002577-4136-4335-bcaf-c883d752fc0d"/>
                     <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
                     <title>6.1 Commonly Observed Adverse Reactions in Double-Blind, Placebo-Controlled Clinical Trials</title>
                     <text>
                        <paragraph>Adverse reactions in either the pediatric or adult double-blind adverse reactions tables may be relevant for both patient populations.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Children and Adolescents</content>
                        </paragraph>
                        <paragraph>Table 4Â lists the adverse reactions reported in 1% or more of methylphenidate hydrochloride extended-release tablets-treated children and adolescent subjects in 4 placebo-controlled, double-blind clinical trials.</paragraph>
                        <table width="800px">
                           <caption>Table 4. Adverse Reactions Reported by â¥1% of Methylphenidate Hydrochloride Extended-Release Tablets-Treated Children and Adolescent Subjects in 4 Placebo-Controlled, Double-Blind Clinical Trials of Methylphenidate Hydrochloride Extended-Release Tablets</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Toprule">
                                    <content styleCode="bold">System/Organ Class</content>
                                    <br/>
            Â  Â Adverse Reaction</td>
                                 <td align="center" styleCode=" Toprule">
                                    <content styleCode="bold">Methylphenidate Hydrochloride <br/>
            Extended-Release Tablets<br/>
                                    </content>
                                    <content styleCode="bold">(n=321)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                                 <td align="center" styleCode=" Toprule">
                                    <content styleCode="bold">
                                       <br/>
            Placebo</content>
                                    <br/>
                                    <content styleCode="bold">(n=318)</content>
                                    <br/>
                                    <content styleCode="bold">%</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Toprule">
                                    <content styleCode="bold">Gastrointestinal Disorders</content>
                                    <br/>
            Â  Â Abdominal pain upper<br/>
            Â  Â Vomiting</td>
                                 <td align="center" styleCode=" Toprule">
                                    <br/>
            6.2<br/>
            2.8</td>
                                 <td align="center" styleCode=" Toprule">
                                    <br/>
            3.8<br/>
            1.6</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">General Disorders and Administration Site Conditions</content>
                                    <br/>
            Â  Â Pyrexia</td>
                                 <td align="center">
                                    <br/>
            2.2</td>
                                 <td align="center">
                                    <br/>
            0.9</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Infections and Infestations</content>
                                    <br/>
            Â  Â Nasopharyngitis</td>
                                 <td align="center">
                                    <br/>
            2.8</td>
                                 <td align="center">
                                    <br/>
            2.2</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Nervous System Disorders</content>
                                    <br/>
            Â  Â Dizziness</td>
                                 <td align="center">
                                    <br/>
            1.9</td>
                                 <td align="center">
                                    <br/>
            0</td>
                              </tr>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Psychiatric Disorders</content>
                                    <br/>
            Â  Â Insomnia*</td>
                                 <td align="center">
                                    <br/>
            2.8</td>
                                 <td align="center">
                                    <br/>
            0.3</td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule">
                                    <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders</content>
                                    <br/>
            Â  Â Cough<br/>
            Â  Â Oropharyngeal pain</td>
                                 <td align="center" styleCode=" Botrule">
                                    <br/>
            1.9<br/>
            1.2</td>
                                 <td align="center" styleCode=" Botrule">
                                    <br/>
            0.9<br/>
            0.9</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*Terms of Initial insomnia (methylphenidate hydrochloride extended-release tablets =0.6%) and Insomnia (methylphenidate hydrochloride extended-release tablets =2.2%) are combined into Insomnia.</paragraph>
                        <paragraph>The majority of adverse reactions were mild to moderate in severity.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>Table 5Â lists the adverse reactions reported in 1% or more of methylphenidate hydrochloride extended-release tablets-treated adults in 2 placebo-controlled, double-blind clinical trials.</paragraph>
                        <table width="1000px">
                           <caption>Table 5. Adverse Reactions Reported by â¥1% of Methylphenidate Hydrochloride Extended-Release Tablets-Treated Adult Subjects in 2 Placebo-Controlled, Double-Blind Clinical Trials*</caption>
                           <col/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">System/Organ Class<br/>
                                       </content>Â  Â Adverse Reaction</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Methylphenidate Hydrochloride <br/>
            Extended-Release<br/>
            Tablets <br/>
            (</content>
                                       <content styleCode="bold">n=415)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>
                                          <br/>
            Placebo <br/>
            (n=212)</content>
                                    </paragraph>
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Cardiac Disorders<br/>
                                       </content>Â  Â Tachycardia<br/>
            Â  Â Palpitations</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>4.8<br/>
            3.1</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>0<br/>
            0.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Ear and Labyrinth Disorders<br/>
                                       </content>Â  Â Vertigo</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Eye Disorders<br/>
                                       </content>Â  Â Vision blurred</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>0.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Gastrointestinal Disorders<br/>
                                       </content>Â  Â Dry mouth<br/>
            Â  Â Nausea<br/>
            Â  Â Dyspepsia<br/>
            Â  Â Vomiting<br/>
            Â  Â Constipation</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>14.0<br/>
            12.8<br/>
            2.2<br/>
            1.7<br/>
            1.4</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3.8<br/>
            3.3<br/>
            0.9<br/>
            0.5<br/>
            0.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">General Disorders and Administration Site Conditions<br/>
                                       </content>Â  Â Irritability</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>5.8</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Infections and Infestations<br/>
                                       </content>Â  Â Upper respiratory tract infection</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>2.2</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>0.9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Investigations<br/>
                                       </content>Â  Â Weight decreased</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6.5</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3.3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Metabolism and Nutrition Disorders<br/>
                                       </content>Â  Â Decreased appetite<br/>
            Â  Â Anorexia</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>25.3<br/>
            1.7</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6.6<br/>
            0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Musculoskeletal and Connective Tissue Disorders<br/>
                                       </content>Â  Â Muscle tightness</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>
            1.9</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>
            0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Nervous System Disorders<br/>
                                       </content>Â  Â Headache<br/>
            Â  Â Dizziness<br/>
            Â  Â Tremor<br/>
            Â  Â Paresthesia<br/>
            Â  Â Sedation<br/>
            Â  Â Tension headache</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>22.2<br/>
            6.7<br/>
            2.7<br/>
            1.2<br/>
            1.2<br/>
            1.2</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>15.6<br/>
            5.2<br/>
            0.5<br/>
            0<br/>
            0<br/>
            0.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Psychiatric Disorders<br/>
                                       </content>Â  Â Insomnia<br/>
            Â  Â Anxiety<br/>
            Â  Â Initial insomnia<br/>
            Â  Â Depressed mood<br/>
            Â  Â Nervousness<br/>
            Â  Â Restlessness<br/>
            Â  Â Agitation<br/>
            Â  Â Aggression<br/>
            Â  Â Bruxism<br/>
            Â  Â Depression<br/>
            Â  Â Libido decreased<br/>
            Â  Â Affect lability<br/>
            Â  Â Confusional state<br/>
            Â  Â Tension</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>12.3<br/>
            8.2<br/>
            4.3<br/>
            3.9<br/>
            3.1<br/>
            3.1<br/>
            2.2<br/>
            1.7<br/>
            1.7<br/>
            1.7<br/>
            1.7<br/>
            1.4<br/>
            1.2<br/>
            1.2</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6.1<br/>
            2.4<br/>
            2.8<br/>
            1.4<br/>
            0.5<br/>
            0<br/>
            0.5<br/>
            0.5<br/>
            0.5<br/>
            0.9<br/>
            0.5<br/>
            0.9<br/>
            0.5<br/>
            0.5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <content styleCode="bold">Respiratory, Thoracic and Mediastinal Disorders<br/>
                                       </content>Â  Â Oropharyngeal pain</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1.7</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>1.4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule">
                                    <paragraph>
                                       <content styleCode="bold">Skin and Subcutaneous Tissue Disorders<br/>
                                       </content>Â  Â Hyperhidrosis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule">
                                    <paragraph>5.1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule">
                                    <paragraph>0.9</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Included doses up to 108 mg.</paragraph>
                        <paragraph>The majority of ADRs were mild to moderate in severity.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a4768ce1-0ab5-44d4-8bec-6ebf9315eae0">
                     <id root="7f7dc51f-28d7-4c90-9459-f150ee4c4cee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Other
Adverse Reactions Observed in Methylphenidate Hydrochloride Extended-Release Tablets Clinical
Trials</title>
                     <text>
                        <paragraph>This section includes adverse reactions reported by methylphenidate hydrochloride extended-release tablets-treated subjects in double-blind trials that do not meet the criteria specified for Table 4 or Table 5 and all adverse reactions reported by methylphenidate hydrochloride extended-release tablets-treated subjects who participated in open-label and postmarketing clinical trials.</paragraph>
                        <paragraph>Blood and Lymphatic System Disorders: Leukopenia 
</paragraph>
                        <paragraph>Eye Disorders:<content styleCode="italics">Â </content>Accommodation disorder, Dry eye 
</paragraph>
                        <paragraph>Vascular Disorders: Hot flush 
</paragraph>
                        <paragraph>Gastrointestinal Disorders:<content styleCode="italics">Â </content>Abdominal discomfort, Abdominal pain, Diarrhea </paragraph>
                        <paragraph>General Disorders and Administrative Site Conditions: Asthenia, Fatigue, Feeling jittery, Thirst 
</paragraph>
                        <paragraph>Infections and Infestations: Sinusitis 
</paragraph>
                        <paragraph>Investigations: Alanine aminotransferase increased, Blood pressure increased, Cardiac murmur, Heart rate increased 
</paragraph>
                        <paragraph>Musculoskeletal and Connective Tissue Disorders: Muscle spasmsÂ  
</paragraph>
                        <paragraph>Nervous System Disorders: Lethargy, Psychomotor hyperactivity, Somnolence 
</paragraph>
                        <paragraph>Psychiatric Disorders: Anger, Hypervigilance, Mood altered, Mood swings, Panic attack, Sleep disorder, Tearfulness, Tic 
</paragraph>
                        <paragraph>Reproductive System and Breast Disorders: Erectile dysfunction 
</paragraph>
                        <paragraph>Respiratory, Thoracic and Mediastinal Disorders: Dyspnea 
</paragraph>
                        <paragraph>Skin and Subcutaneous Tissue Disorders: Rash, Rash macular 
</paragraph>
                        <paragraph>Vascular Disorders: Hypertension </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_cb0289f1-bf2d-4621-9f06-0c367e3fc2d3">
                     <id root="0188c5b7-41ac-4ee9-81a2-b6a00941ee6a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Discontinuation Due to Adverse Reactions</title>
                     <text>
                        <paragraph>Adverse reactions in the 4 placebo-controlled studies of children and adolescents leading to discontinuation occurred in 2 methylphenidate hydrochloride extended-release tablets patients (0.6%) including depressed mood (1, 0.3%) and headache and insomnia (1, 0.3%), and 6 placebo patients (1.9%) including headache and insomnia (1, 0.3%), irritability (2, 0.6%), headache (1, 0.3%), psychomotor hyperactivity (1, 0.3%), and tic (1, 0.3%).</paragraph>
                        <paragraph>In the 2 placebo-controlled studies of adults, 25 methylphenidate hydrochloride extended-release tablets patients (6.0%) and 6 placebo patients (2.8%) discontinued due to an adverse reaction. Those events with an incidence of &gt;0.5% in the methylphenidate hydrochloride extended-release tablets patients included anxiety (1.7%), irritability (1.4%), blood pressure increased (1.0%), and nervousness (0.7%). In placebo patients, blood pressure increased and depressed mood had an incidence of &gt;0.5% (0.9%).Â  </paragraph>
                        <paragraph>In the 11 open-label studies of children, adolescents, and adults, 266 methylphenidate hydrochloride <br/> extended-release tablets patients (7.0%) discontinued due to an adverse reaction. Those events with an incidence of &gt;0.5% included insomnia (1.2%), irritability (0.8%), anxiety (0.7%), decreased appetite (0.7%), and tic (0.6%).</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7f7106a9-7833-480f-b361-8705ecb2b079">
                     <id root="56c10ccd-cada-469d-8a4d-41b857191b36"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.4 Blood Pressure and Heart Rate Increases</title>
                     <text>
                        <paragraph>In the laboratory classroom clinical trials in children (Studies 1 and 2), both methylphenidate hydrochloride extended-release once daily and methylphenidate three times daily increased resting pulse by an average of 2 to 6 bpm and produced average increases of systolic and diastolic blood pressure of roughly 1 to 4 mm Hg during the day, relative to placebo. In the placebo-controlled adolescent trial (Study 4), mean increases from baseline in resting pulse rate were observed with methylphenidate hydrochloride extended-release and placebo at the end of the double-blind phase (5 and 3 beats/minute, respectively). Mean increases from baseline in blood pressure at the end of the double-blind phase for methylphenidate hydrochloride extended-release and placebo-treated patients were 0.7 and 0.7 mm Hg (systolic) and 2.6 and 1.4 mm Hg (diastolic), respectively. In one placebo-controlled study in adults (Study 6), dose-dependent mean increases of 3.9 to 9.8 bpm from baseline in standing pulse rate were observed with methylphenidate hydrochloride extended-release at the end of the double-blind treatment vs. an increase of 2.7 beats/minute with placebo. Mean changes from baseline in standing blood pressure at the end of double-blind treatment ranged from 0.1 to 2.2 mm Hg (systolic) and -0.7 to 2.2 mm Hg (diastolic) for methylphenidate hydrochloride extended-release and was 1.1 mm Hg (systolic) and -1.8 mm Hg (diastolic) for placebo. In a second placebo-controlled study in adults (Study 5), mean changes from baseline in resting pulse rate were observed for methylphenidate hydrochloride Â extended-release and placebo at the end of the double-blind treatment (3.6 and â1.6 beats/minute, respectively). Mean changes from baseline in blood pressure at the end of the doubleâblind treatment for methylphenidate hydrochloride Â extended-release and placebo-treated patients were â1.2 and â0.5 mm Hg (systolic) and 1.1 and 0.4 mm Hg (diastolic), respectivelyÂ <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_efd2892f-c22f-4333-afee-a38a424fc274">
                     <id root="4db2ed7c-05eb-4e05-8cd8-f3b178420cf7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.5 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following additional adverse reactions have been identified during post-approval use of methylphenidate hydrochloride extended-release tablets. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency:</paragraph>
                        <paragraph>Blood and Lymphatic System Disorders: Pancytopenia, Thrombocytopenia, Thrombocytopenic purpura </paragraph>
                        <paragraph>Cardiac Disorders: Angina pectoris, Bradycardia, Extrasystoles, Supraventricular tachycardia, Ventricular extrasystoles </paragraph>
                        <paragraph>Eye Disorders: Diplopia,Â Increased intraocular pressure, Mydriasis, Visual impairment</paragraph>
                        <paragraph>General Disorders: Chest pain, Chest discomfort, Drug effect decreased, Hyperpyrexia, Therapeutic response decreased</paragraph>
                        <paragraph>Hepatobiliary disorders: Hepatocellular injury, Acute hepatic failure</paragraph>
                        <paragraph>Immune System Disorders: Hypersensitivity reactions such as Angioedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritus NEC, Rashes, Eruptions, and Exanthemas NEC </paragraph>
                        <paragraph>Investigations: Blood alkaline phosphatase increased, Blood bilirubin increased, Hepatic enzyme increased, Platelet count decreased, White blood cell count abnormal </paragraph>
                        <paragraph>Musculoskeletal, Connective Tissue and Bone Disorders: Arthralgia, Myalgia,Â Muscle twitching, Rhabdomyolysis Â </paragraph>
                        <paragraph>Nervous System Disorders: Convulsion, Grand mal convulsion, Dyskinesia, Serotonin syndrome in combination with serotonergic drugs, Motor and Verbal Tics</paragraph>
                        <paragraph>Psychiatric Disorders: Disorientation, Hallucination, Hallucination auditory, Hallucination visual, Mania, Logorrhea, Libido changes</paragraph>
                        <paragraph>Reproductive System and Breast Disorders: Priapism</paragraph>
                        <paragraph>Skin and Subcutaneous Tissue Disorders: Alopecia, Erythema </paragraph>
                        <paragraph>Vascular Disorders: Raynaud's phenomenon </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c5ad7e6f-e65a-44af-aecc-ee7f1b1f7611">
               <id root="f69d18b6-ce9b-4306-a900-fb059e46511c"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Methylphenidate hydrochlorideÂ extended-release tablets may increase blood pressure; use cautiously with vasopressorsÂ (<linkHtml href="#LINK_a4fb77f8-9eee-4809-b8a4-f7b9e78ac864">7.2</linkHtml>)
    </item>
                           <item>Inhibition of metabolism of coumarin anticoagulants, anticonvulsants, and some antidepressants (<linkHtml href="#LINK_4dc42999-2d17-4f08-b184-21b0f391ddb8">7.3</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_a2e7e795-e2d9-4edc-beff-0d1d2b7e5d2c">
                     <id root="b0d776ee-64a3-463a-a5c6-2c0d9062da00"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 MAO Inhibitors</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets should not be used in patients being treated (currently or within the preceding 2 weeks) with MAO inhibitors <content styleCode="italics">[see Contraindications (<linkHtml href="#LINK_a0b20943-1499-4cdd-938c-8c1d4d12ac47">4.2</linkHtml>)]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_1e73f72f-77bd-4428-8f9c-9f167b6e45da">
                     <id root="6eae0504-b8ac-4fe1-a535-d66f88b26f9d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Vasopressor Agents</title>
                     <text>
                        <paragraph>Because of possible increases in blood pressure, methylphenidate hydrochloride extended-release tablets should be used cautiously with vasopressor agents <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b92519ff-9458-421f-81b3-fca364a4324a">5.3</linkHtml>)]</content>.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0874f6d8-2e78-4379-b4c5-736206a0ea88">
                     <id root="3bdc8af8-8059-4d99-9c22-cb7b16b7b121"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Coumarin Anticoagulants, Antidepressants, and Selective Serotonin Reuptake Inhibitors</title>
                     <text>
                        <paragraph>Human pharmacologic studies have shown that methylphenidate may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (e.g., phenobarbital, phenytoin, primidone), and some antidepressants (tricyclics and selective serotonin reuptake inhibitors). Downward dose adjustment of these drugs may be required when given concomitantly with methylphenidate. It may be necessary to adjust the dosage and monitor plasma drug concentrations (or, in the case of coumarin, coagulation times), when initiating or discontinuing concomitant methylphenidate.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c03ee543-768a-4328-bafa-d3c350f6a4d0">
                     <id root="30aa10e0-b4b9-4507-a132-7958c0038f2b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.4 Halogenated Anesthetics</title>
                     <text>
                        <paragraph>Concomitant use of halogenated anesthetics and methylphenidate hydrochloride extended-release tablets may increase the risk of sudden blood pressure and heart rate increase during surgery. Monitor blood pressure and avoid use of methylphenidate hydrochloride extended-release tablets in patients being treated with anesthetics on the day of surgery.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8c9e099c-d1c3-4852-97b3-d18d39304310">
                     <id root="e3e659b4-bc63-476c-8f96-bb034d7497ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.5 Risperidone</title>
                     <text>
                        <paragraph>Combined use of methylphenidate with risperidone when there is a change, whether an increase or decrease, in dosage of either or both medications, may increase the risk of extrapyramidal symptoms (EPS). Monitor for signs of EPS.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_1aaac868-6fab-42be-8d95-996dd689ed46">
               <id root="30e52fbb-8ae5-4754-a600-50e9f0635f38"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240402"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disk">
                           <item>Caution should be exercised if administered to nursing mothers (<linkHtml href="#LINK_1a51bbd3-9bad-4895-8bb5-0cb9ca4eee4f">8.3</linkHtml>)</item>
                           <item>Safety and efficacy has not been established in children less than six years old or elderly patients greater than 65 years of age (<linkHtml href="#LINK_82e8d9dc-0b3d-4f74-8899-a32dd469f18e">8.4</linkHtml> and <linkHtml href="#LINK_6c9d241e-f569-4798-8b4c-874c0bcc8a2b">8.5</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_f4c80d41-aff9-4588-9f5c-fca6c6b1ed03">
                     <id root="17360a2a-3cf4-48f2-abba-633451341e25"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Category C</content>
                        </paragraph>
                        <paragraph>Methylphenidate has been shown to have teratogenic effects in rabbits when given in doses of 200 mg/kg/day, which is approximately 100 times and 40 times the maximum recommended human dose on a mg/kg and mg/m<sup>2</sup>Â basis, respectively.</paragraph>
                        <paragraph>A reproduction study in rats revealed no evidence of harm to the fetus at oral doses up to 30 mg/kg/day, approximately 15-fold and 3-fold the maximum recommended human dose of methylphenidate hydrochloride extended-release tablets on a mg/kg and mg/m<sup>2</sup> basis, respectively. The approximate plasma exposure to methylphenidate plus its main metabolite PPAA in pregnant rats was 1-2 times that seen in trials in volunteers and patients with the maximum recommended dose of methylphenidate hydrochloride extended-release tablets based on the AUC.</paragraph>
                        <paragraph>The safety of methylphenidate for use during human pregnancy has not been established. There are no adequate and well-controlled studies in pregnant women. Methylphenidate hydrochloride extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_18fbf75b-1c4e-4d7c-9cd5-accdd972f4aa">
                     <id root="87d9c601-642c-4c6d-88c4-594088be6a95"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Labor and Delivery</title>
                     <text>
                        <paragraph>The effect of methylphenidate hydrochloride extended-release tablets on labor and delivery in humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9d3e26a4-a658-480d-b9f3-d0e590d0cddb">
                     <id root="4c2ae16a-60f7-4d74-96a2-1a579552311d"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>It is not known whether methylphenidate is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised if methylphenidate hydrochlorideÂ extended-release tablets are administered to a nursing woman. </paragraph>
                        <paragraph>In lactating female rats treated with a single oral dose of 5 mg/kg radiolabeled methylphenidate, radioactivity (representing methylphenidate and/or its metabolites) was observed in milk and levels were generally similar to those in plasma.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b2dc0fea-27e3-40a8-8da4-409b5c82333b">
                     <id root="ac96a116-6c80-459a-96e3-7afc42f551a7"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets should not be used in children under six years, since safety and efficacy in this age group have not been established. Long-term effects of methylphenidate in children have not been well established.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_628151f6-40a2-4fad-906f-3a41f0e930df">
                     <id root="035d5ba6-9292-4c41-9b91-1830cf5dec77"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets have not been studied in patients greater than 65 years of age.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_88749d2e-4cfd-45ca-92aa-e411b66b6b11">
               <id root="0e09993e-f75d-40d2-b38f-fe3c5498daab"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE
</title>
               <effectiveTime value="20240402"/>
               <component>
                  <section ID="LINK_f81c0021-14cd-41ed-9b57-332f2b48fe39">
                     <id root="223d6783-7be7-45cb-9968-55cf6f1f1f86"/>
                     <code code="34085-1" codeSystem="2.16.840.1.113883.6.1" displayName="CONTROLLED SUBSTANCE SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets contains methylphenidate, a Schedule II controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2de45e7d-f3d8-47ab-8e03-328793cd40b6">
                     <id root="804766bb-4950-44a3-ac3d-b15cbfded8d9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets has a high potential for abuse and misuse which can lead to the development of a substance use disorder, including addiction <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>)]</content>. Methylphenidate hydrochloride extended-release tablets can be diverted for non-medical use into illicit channels or distribution.</paragraph>
                        <paragraph>Abuse is the intentional non-therapeutic use of a drug, even once, to achieve a desired psychological or physiological effect. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence.</paragraph>
                        <paragraph>Misuse and abuse of methylphenidate may cause increased heart rate, respiratory rate, or blood pressure; sweating; dilated pupils; hyperactivity; restlessness; insomnia; decreased appetite; loss of coordination; tremors; flushed skin; vomiting; and/or abdominal pain. Anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation have also been observed with CNS stimulants abuse and/or misuse. Misuse and abuse of CNS stimulants, including methylphenidate hydrochloride extended-release tablets, can result in overdose and death <content styleCode="italics">[see Overdosage (<linkHtml href="#LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">10</linkHtml>)]</content>, and this risk is increased with higher doses or unapproved methods of administration, such as snorting or injection.</paragraph>
                        <paragraph>In two placebo-controlled human abuse potential studies, single oral doses of methylphenidate hydrochloride extended-release tabletsÂ  were compared to single oral doses of immediate-release methylphenidate (IR MPH) and placebo in subjects with a history of recreational stimulant use to assess relative abuse potential. For the purpose of this assessment, the response for each of the subjective measures was defined as the maximum effect within the first 8 hours after dose administration.</paragraph>
                        <paragraph>In one study (n=40), both methylphenidate hydrochloride extended-release tablets (108 mg) and 60 mg IR MPH compared to placebo produced statistically significantly greater responses on the five subjective measures suggestive of abuse potential. In comparisons between the two active treatments, however, methylphenidate hydrochlorideÂ extended-release tablets (108 mg) produced variable responses on positive subjective measures that were either statistically indistinguishable from (Abuse Potential, Drug Liking, Amphetamine, and Morphine Benzedrine Group [Euphoria]) or statistically less than (Stimulation â Euphoria) responses produced by 60 mg IR MPH.</paragraph>
                        <paragraph>In another study (n=49), both doses of methylphenidate hydrochloride extended-release tablets (54 mg and 108 mg) and both doses of IR MPH (50 mg and 90 mg) produced statistically significantly greater responses compared to placebo on the two primary scales used in the study (Drug Liking, Euphoria). When doses of methylphenidate hydrochloride extended-release tablets (54 mg and 108 mg) were compared to IR MPH (50 mg and 90 mg), respectively, methylphenidate hydrochloride extended-release tablets produced statistically significantly lower subjective responses on these two scales than IR MPH. Methylphenidate hydrochloride extended-release tablets (108 mg) produced responses that were statistically indistinguishable from the responses on these two scales produced by IR MPH (50 mg). Differences in subjective responses to the respective doses should be considered in the context that only 22% of the total amount of methylphenidate in methylphenidate hydrochloride extended-release tablets is available for immediate-release from the drug overcoat <content styleCode="italics">[see System Components and Performance (<linkHtml href="#www.splportal.comLINK_0ed8acf0-bb0e-4a63-9e57-abd140f63cb4">11.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Although these findings reveal a relatively lower response to methylphenidate hydrochloride extended-release tablets on subjective measures suggestive of abuse potential compared to IR MPH at roughly equivalent total MPH doses, the relevance of these findings to the abuse potential of methylphenidate hydrochloride extended-release tablets in the community is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5fb8dbf0-c48a-4641-95d5-2481167c3a9e">
                     <id root="601a2c6e-fe45-4b9d-9f8f-0fa8c1093cc6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Physical Dependence</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets may produce physical dependence. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including methylphenidate hydrochloride extended-release tablets include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Tolerance</content>
                        </paragraph>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets may produce tolerance. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">
               <id root="1d728ecb-b0a7-422c-a421-5ba725f162aa"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE
</title>
               <effectiveTime value="20240402"/>
               <component>
                  <section ID="LINK_f3e46db4-4271-4a67-8975-c66f5b60a13b">
                     <id root="83398780-ad49-442e-8667-f5a2db8b89b1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.1 Clinical Effects of Overdose</title>
                     <text>
                        <paragraph>Overdose of CNS stimulants is characterized by the following sympathomimetic effects: </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Cardiovascular effects including tachyarrhythmias, and hypertension or hypotension. Vasospasm, myocardial infarction, or aortic dissection may precipitate sudden cardiac death. Takotsubo cardiomyopathy may develop.</item>
                           <item>CNS effects including psychomotor agitation, confusion, and hallucinations. Serotonin syndrome, seizures, cerebral vascular accidents, and coma may occur.</item>
                           <item>Life-threatening hyperthermia (temperatures greater than 104Â°F) and rhabdomyolysis may develop.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_00c47dd3-1117-4fca-b40a-658f45f23539">
                     <id root="dc946df7-1727-4500-b202-601e5fce9681"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>10.2
Overdose Management</title>
                     <text>
                        <paragraph>Consider the possibility of multiple drug ingestion. The pharmacokinetic profile of methylphenidate hydrochloride extended-release tablets should be considered when treating patients with overdose. Because methylphenidate has a large volume of distribution and is rapidly metabolized, dialysis is not useful. Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_231449c4-e7a9-4a81-91e8-e29190613ca8">
               <id root="974bb8e1-f6a7-448a-9a17-a13d40f86dba"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride extended-release tablets, USP are a central nervous system (CNS) stimulant. Methylphenidate hydrochloride extended-release tablets, USP are available in four tablet strengths. Each extended-release tablet for once-a-day oral administration contains 18 mg, 27 mg, 36 mg, or 54 mg of methylphenidate hydrochloride, USP and is designed to have a 12-hour duration of effect. Chemically, methylphenidate hydrochloride, USP is d,l (racemic) methyl Î±-phenyl-2-piperidineacetate hydrochloride. Its molecular formula is C<sub>14</sub>H<sub>19</sub>NO<sub>2</sub>â¢HCl. Its structural formula is: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>Methylphenidate hydrochloride, USP is a white, odorless crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77. </paragraph>
                  <paragraph>Methylphenidate hydrochloride extended-release tablets, USP also contain the following inert ingredients: colloidal silicon dioxide, fumaric acid, hypromellose 2208, hypromellose 2910, lactose monohydrate, magnesium stearate, methacrylic acid copolymer Type A, methacrylic acid copolymer Type B, talc, titanium dioxide, and triethyl citrate. The 18 mg strength also contains iron oxide red, iron oxide yellow, polyethylene glycol 3350, and polyvinyl alcohol. The 27 mg strength also contains FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, iron oxide black, iron oxide yellow, polyethylene glycol 3350, and polyvinyl alcohol. The 36 mg strength also contains triacetin. The 54 mg strength also contains iron oxide red, polyethylene glycol 3350, and polyvinyl alcohol. The imprinting ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.</paragraph>
                  <paragraph>Meets USP Dissolution Test 11. </paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Structural Formula</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="LINK_0ed8acf0-bb0e-4a63-9e57-abd140f63cb4">
                     <id root="50335e92-0131-448b-8cab-c0044b209cf9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>11.1 System Components and Performance</title>
                     <text>
                        <paragraph>Methylphenidate hydrochloride extended-release tablets uses osmotic pressure to deliver methylphenidate HCl at a controlled rate. The system, which resembles a conventional tablet in appearance, comprises an osmotically active trilayer core surrounded by a semipermeable membrane with an immediate-release drug overcoat. The trilayer core is composed of two drug layers containing the drug and excipients, and a push layer containing osmotically active components. There is a precision-laser drilled orifice on the drug-layer end of the tablet. In an aqueous environment, such as the gastrointestinal tract, the drug overcoat dissolves within one hour, providing an initial dose of methylphenidate. Water permeates through the membrane into the tablet core. As the osmotically active polymer excipients expand, methylphenidate is released through the orifice. The membrane controls the rate at which water enters the tablet core, which in turn controls drug delivery. Furthermore, the drug release rate from the system increases with time over a period of 6 to 7 hours due to the drug-concentration gradient incorporated into the two drug layers of methylphenidate hydrochloride extended-release tablets. The biologically inert components of the tablet remain intact during gastrointestinal transit and are eliminated in the stool as a tablet shell along with insoluble core components. It is possible that Methylphenidate hydrochloride extended-release tablets may be visible on abdominal x-rays under certain circumstances, especially when digital enhancing techniques are utilized.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_564faa24-54df-4a1e-b064-5159cbeb6bd4">
               <id root="2f2878be-f086-48b9-ac05-9a409683b65a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY
</title>
               <effectiveTime value="20240402"/>
               <component>
                  <section ID="LINK_12c8cfef-18c9-4823-8f4a-e4fc2bb1fde3">
                     <id root="cc488db4-ac8d-4603-b355-cb4c4a4736ad"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Methylphenidate hydrochlorideÂ is a central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_18ae4c32-1a86-414f-b1e4-b46b1f3da387">
                     <id root="c8dcd1d4-b519-48ee-8e53-02f5869e1417"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics
</title>
                     <text>
                        <paragraph>Methylphenidate is a racemic mixture comprised of the d- and l-isomers. The d-isomer is more pharmacologically active than the l-isomer.
</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a827c4c7-050e-44fd-b668-660607cb901d">
                     <id root="ea5aa113-9f6f-4502-9757-33f892978f8c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Methylphenidate is readily absorbed. Following oral administration of methylphenidate hydrochloride extended-release tablets, plasma methylphenidate concentrations increase rapidly, reaching an initial maximum at about 1 hour, followed by gradual ascending concentrations over the next 5 to 9 hours, after which a gradual decrease begins. Mean times to reach peak plasma concentrations across all doses of methylphenidate hydrochloride extended-release tablets occurred between 6 and 10 hours.</paragraph>
                        <paragraph>Methylphenidate hydrochloride extended-release once daily minimizes the fluctuations between peak and trough concentrations associated with immediate-release methylphenidate three times daily (see Figure 1). The relative bioavailability of methylphenidate hydrochloride extended-release tablets onceÂ daily and methylphenidate three times daily in adults is comparable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1. Mean methylphenidate plasma concentrations in 36 adults, following a single dose of Methylphenidate Hydrochloride Extended-Release Tablets 18 mg Once Daily and immediate-release methylphenidate 5 mg three times daily administered every 4 hours.</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM2"/>
                        <paragraph>The mean single-dose pharmacokinetic parameters in 36 healthy adults following the administration of methylphenidate hydrochloride extended-release tablets 18 mg once daily and methylphenidate 5 mg three times daily are summarized inÂ Table 6.</paragraph>
                        <table width="800pt" cellspacing="0" cellpadding="0">
                           <caption>Table 6. Pharmacokinetic Parameters (Mean Â± SD) After Single Dose in Healthy Adults</caption>
                           <col width="110.5pt"/>
                           <col width="162.65pt"/>
                           <col width="1.4in"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Parameters</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Methylphenidate HydrochlorideÂ Extended-Release Tablets<br/>
                                       </content>
                                       <content styleCode="bold">(18 mg once daily)<br/>
                                       </content>
                                       <content styleCode="bold">(n=36)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule">
                                    <paragraph>
                                       <content styleCode="bold">Methylphenidate<br/>
                                       </content>
                                       <content styleCode="bold">(5 mg threeÂ </content>
                                       <content styleCode="bold">times daily)<br/>
                                       </content>
                                       <content styleCode="bold">(n=35)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <paragraph>C<sub>maxÂ </sub>(ng/mL)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3.7 Â± 1.0</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>4.2 Â± 1.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <paragraph>T<sub>maxÂ </sub>(h)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6.8 Â± 1.8</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>6.5 Â± 1.8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <paragraph>AUC<sub>infÂ </sub>(ngâ¢h/mL)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>41.8 Â± 13.9</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>38.0 Â± 11.0</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center">
                                    <paragraph>t<sub>&amp;frac12;Â </sub>(h)</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3.5 Â± 0.4</paragraph>
                                 </td>
                                 <td align="center">
                                    <paragraph>3.0 Â± 0.5</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The pharmacokinetics of methylphenidate hydrochloride extended-release tablets were evaluated in healthy adults following single- and multiple-dose administration (steady state) of doses up to 144 mg/day. The mean half-life was about 3.6 hours. No differences in the pharmacokinetics of methylphenidate hydrochloride extended-release tablets were noted following single and repeated once-daily dosing, indicating no significant drug accumulation. The AUC and t<sub>&amp;frac12;</sub>Â following repeated once-daily dosing are similar to those following the first dose of methylphenidate hydrochloride extended-release tablets in a dose range of 18 to 144 mg.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Dose Proportionality</content>
                        </paragraph>
                        <paragraph>Following administration of methylphenidate hydrochloride extended-release tablets in single doses of 18, 36, and 54 mg/day to healthy adults, C<sub>max</sub>Â and AUC<sub>(0-inf)</sub>Â of d-methylphenidate were proportional to dose, whereas l-methylphenidate C<sub>max</sub>Â and AUC<sub>(0-inf)</sub>Â increased disproportionately with respect to dose. Following administration of methylphenidate hydrochloride extended-release tablets, plasma concentrations of theÂ l-isomer were approximately 1/40 the plasma concentrations of the d-isomer.</paragraph>
                        <paragraph>In healthy adults, single and multiple dosing of once-daily methylphenidate hydrochloride extended-release tablets doses from 54 to 144 mg/day resulted in linear and dose-proportional increases in C<sub>max</sub>Â and AUC<sub>inf</sub>Â for total methylphenidate (MPH) and its major metabolite, Î±-phenyl-piperidine acetic acid (PPAA). There was no time dependency in the pharmacokinetics of methylphenidate. The ratio of metabolite (PPAA) to parent drug (MPH) was constant across doses from 54 to 144 mg/day, both after single dose and upon multiple dosing.</paragraph>
                        <paragraph>In a multiple-dose study in adolescent ADHD patients aged 13 to 16 administered their prescribed dose (18 to 72 mg/day) of methylphenidate hydrochloride extended-release tablets, mean C<sub>max</sub>Â and AUC<sub>TAU</sub>Â of d- and total methylphenidate increased proportionally with respect to dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Plasma methylphenidate concentrations in adults and adolescents decline biexponentially following oral administration. The half-life of methylphenidate in adults and adolescents following oral administration of methylphenidate hydrochloride extended-release tablets was approximately 3.5 hours.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Metabolism and Excretion</content>
                        </paragraph>
                        <paragraph>In humans, methylphenidate is metabolized primarily by de-esterification to PPAA, which has little or no pharmacologic activity. In adults the metabolism of methylphenidate hydrochloride extended-release tablets once daily as evaluated by metabolism to PPAA is similar to that of methylphenidate three times daily. The metabolism of single and repeated once-daily doses of methylphenidate hydrochloride extended-release tablets is similar.</paragraph>
                        <paragraph>After oral dosing of radiolabeled methylphenidate in humans, about 90% of the radioactivity was recovered in urine. The main urinary metabolite was PPAA, accounting for approximately 80% of the dose.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Food Effects</content>
                        </paragraph>
                        <paragraph>In patients, there were no differences in either the pharmacokinetics or the pharmacodynamic performance of methylphenidate hydrochloride extended-release tablets when administered after a high-fat breakfast. There is no evidence of dose dumping in the presence or absence of food.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Alcohol Effect</content>
                        </paragraph>
                        <paragraph>AnÂ <content styleCode="italics">in vitroÂ </content>study was conducted to explore the effect of alcohol on the release characteristics of methylphenidate from the methylphenidate hydrochloride extended-release tablets 18 mg tablet dosage form. At an alcohol concentration up to 40% there was no increased release of methylphenidate in the first hour. The results with the 18 mg tablet strength are considered representative of the other available tablet strengths.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Special Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Gender</content>
                        </paragraph>
                        <paragraph>In healthy adults, the mean dose-adjusted AUC<sub>(0-inf)</sub>Â values for methylphenidate hydrochloride extended-release tablets were 36.7 ngâ¢h/mL in men and 37.1 ngâ¢h/mL in women, with no differences noted between the two groups.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Race</content>
                        </paragraph>
                        <paragraph>In adults receiving methylphenidate hydrochloride extended-release tablets, dose-adjusted AUC<sub>(0-inf)</sub>Â was consistent across ethnic groups; however, the sample size may have been insufficient to detect ethnic variations in pharmacokinetics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Age</content>
                        </paragraph>
                        <paragraph>Increase in age resulted in increased apparent oral clearance (CL/F) (58% increase in adolescents compared to children). Some of these differences could be explained by body-weight differences among these populations. This suggests that subjects with higher body weight may have lower exposures of total methylphenidate at similar doses.</paragraph>
                        <paragraph>The pharmacokinetics of methylphenidate hydrochloride extended-release tablets has not been studied in children less than 6 years of age.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal Insufficiency</content>
                        </paragraph>
                        <paragraph>There is no experience with the use of methylphenidate hydrochloride extended-release tablets in patients with renal insufficiency. After oral administration of radiolabeled methylphenidate in humans, methylphenidate was extensively metabolized and approximately 80% of the radioactivity was excreted in the urine in the form of PPAA. Since renal clearance is not an important route of methylphenidate clearance, renal insufficiency is expected to have little effect on the pharmacokinetics of methylphenidate hydrochloride extended-release tablets.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic Insufficiency</content>
                        </paragraph>
                        <paragraph>There is no experience with the use of methylphenidate hydrochloride extended-release tablets in patients with hepatic insufficiency.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>new</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-2.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_95166913-08a9-4ed3-9690-7e3ac8da03d4">
               <id root="954a7781-aa32-4f81-b962-7e1366d25946"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240402"/>
               <component>
                  <section ID="LINK_5e22a6d0-4bec-45ff-bf92-b4a49023048e">
                     <id root="96b11405-1c19-4842-bdbb-51647157794b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Carcinogenesis</content>
                        </paragraph>
                        <paragraph>In a lifetime carcinogenicity study carried out in B6C3F1 mice, methylphenidate caused an increase in hepatocellular adenomas and, in males only, an increase in hepatoblastomas at a daily dose of approximately 60 mg/kg/day. This dose is approximately 30 times and 4 times the maximum recommended human dose of methylphenidate hydrochloride extended-release on a mg/kg and mg/m<sup>2</sup> basis, respectively. Hepatoblastoma is a relatively rare rodent malignant tumor type. There was no increase in total malignant hepatic tumors. The mouse strain used is sensitive to the development of hepatic tumors, and the significance of these results to humans is unknown. </paragraph>
                        <paragraph>Methylphenidate did not cause any increases in tumors in a lifetime carcinogenicity study carried out in F344 rats; the highest dose used was approximately 45 mg/kg/day, which is approximately 22 times and 5 times the maximum recommended human dose of methylphenidate hydrochloride extended-release on a mg/kg and mg/m<sup>2</sup> basis, respectively. </paragraph>
                        <paragraph>In a 24-week carcinogenicity study in the transgenic mouse strain p53+/-, which is sensitive to genotoxic carcinogens, there was no evidence of carcinogenicity. Male and female mice were fed diets containing the same concentration of methylphenidate as in the lifetime carcinogenicity study; the high-dose groups were exposed to 60 to 74 mg/kg/day of methylphenidate. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Mutagenesis</content>
                        </paragraph>
                        <paragraph>Methylphenidate was not mutagenic in the <content styleCode="italics">in vitro</content> Ames reverse mutation assay or the <content styleCode="italics">in vitro</content> mouse lymphoma cell forward mutation assay. Sister chromatid exchanges and chromosome aberrations were increased, indicative of a weak clastogenic response, in an <content styleCode="italics">in vitro</content> assay in cultured Chinese Hamster Ovary cells. Methylphenidate was negative <content styleCode="italics">in vivo</content> in males and females in the mouse bone marrow micronucleus assay.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Impairment of Fertility</content>
                        </paragraph>
                        <paragraph>Methylphenidate did not impair fertility in male or female mice that were fed diets containing the drug in an 18-week Continuous Breeding study. The study was conducted at doses up to 160 mg/kg/day, approximately 80-fold and 8-fold the highest recommended human dose of methylphenidate hydrochloride extended-release on a mg/kg and mg/m<sup>2 </sup>basis, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8b96cfda-791d-42df-babe-8d0cbb02f945">
               <id root="04bdfeaf-031b-4127-bd36-00d64e1720e8"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride extended-release tablets was demonstrated to be effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in 4 randomized, double-blind, placebo-controlled studies in children and adolescents and 2 double-blind placebo-controlled studies in adults who met the Diagnostic and Statistical Manual 4<sup>th</sup> edition (DSM-IV) criteria for ADHD.</paragraph>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <section ID="LINK_36ed09af-808e-4d5d-bf0a-6b220e1cd254">
                     <id root="76cf348e-cf1e-44fa-bdba-8393c02f9ba7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Children</title>
                     <text>
                        <paragraph>Three double-blind, active- and placebo-controlled studies were conducted in 416 children aged 6 to 12 years. The controlled studies compared methylphenidate hydrochloride extended-release tablets given once daily (18, 36, or 54 mg), methylphenidate given three times daily over 12 hours (15, 30, or 45 mg total daily dose), and placebo in two single-center, 3-week crossover studies (Studies 1 and 2) and in a multicenter, 4-week, parallel-group comparison (Study 3). The primary comparison of interest in all three trials was methylphenidate hydrochloride extended-releaseÂ  tablets versus placebo. </paragraph>
                        <paragraph>Symptoms of ADHD were evaluated by community schoolteachers using the Inattention/Overactivity with Aggression (IOWA) Conners scale. Statistically significant reduction in the Inattention/Overactivity subscale versus placebo was shown consistently across all three controlled studies for methylphenidate hydrochloride extended-release tablets. The scores for methylphenidate hydrochloride extended-release tablets and placebo for the three studies are presented in Figure 2.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2. Mean Community School Teacher IOWA Conners Inattention/Overactivity Scores with Methylphenidate Hydrochloride Extended-Release Tablets Once Daily (18, 36, or 54 mg) and placebo. Studies 1 and 2 involved a 3-way crossover of 1 week per treatment arm. Study 3 involved 4 weeks of parallel-group treatments with a Last Observation Carried Forward analysis at week 4. Error bars represent the mean plus standard error of the mean.</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM3"/>
                        <paragraph>In Studies 1 and 2, symptoms of ADHD were evaluated by laboratory schoolteachers using the SKAMP* laboratory school rating scale. The combined results from these two studies demonstrated statistically significant improvements in attention and behavior in patients treated with methylphenidate hydrochloride extended-release tablets versus placebo that were maintained through 12 hours after dosing. Figure 3 presents the laboratory schoolteacher SKAMP ratings for methylphenidate hydrochloride extended-release tablets and placebo.</paragraph>
                        <paragraph>*Swanson, Kotkin, Agler, M-Fynn, and Pelham</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3. Laboratory School Teacher SKAMP Ratings: Mean (SEM) of Combined Attention (Studies 1 and 2)</content>
                        </paragraph>
                        <renderMultiMedia referencedObject="MM4"/>
                     </text>
                     <effectiveTime value="20240402"/>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Fig. 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-3.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM4">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="image-4.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_8979c135-5ef5-47ca-b072-8da9e35ea7bb">
                     <id root="d9ac1575-6303-4d18-885d-b3379eb5628c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2 Adolescents</title>
                     <text>
                        <paragraph>In a randomized, double-blind, multicenter, placebo-controlled trial (Study 4) involving 177 patients, methylphenidate hydrochloride extended-release tablets was demonstrated to be effective in the treatment of ADHD in adolescents aged 13 to 18 years at doses up to 72 mg/day (1.4 mg/kg/day). Of 220 patients who entered an open 4-week titration phase, 177 were titrated to an individualized dose (maximum of 72 mg/day) based on meeting specific improvement criteria on the ADHD Rating Scale and the Global Assessment of Effectiveness with acceptable tolerability. Patients who met these criteria were then randomized to receive either their individualized dose of methylphenidate hydrochloride extended-release tablets (18 - 72 mg/day, n=87) or placebo (n=90) during a two-week double-blind phase. At the end of this phase, mean scores for the investigator rating on the ADHD Rating Scale demonstrated that methylphenidate hydrochloride extended-release tablets was statistically significantly superior to placebo. </paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d4c46f4e-35d3-4c63-a6cc-10f628c38424">
                     <id root="b0020867-7dbf-43c0-8cc0-65131118ff13"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.3Â  Adults</title>
                     <text>
                        <paragraph>Two double-blind, placebo-controlled studies were conducted in 627 adults aged 18 to 65 years. The controlled studies compared methylphenidate hydrochloride extended-release tablets administered once daily and placebo in a multicenter, parallel-group, 7-week dose-titration study (Study 5) (36 to 108 mg/day) and in a multicenter, parallel-group, 5-week, fixed-dose study (Study 6) (18, 36, and 72 mg/day). </paragraph>
                        <paragraph>Study 5 demonstrated the effectiveness of methylphenidate hydrochloride extended-release tablets in the treatment of ADHD in adults aged 18 to 65 years at doses from 36 mg/day to 108 mg/day based on the change from baseline to final study visit on the Adult ADHD Investigator Rating Scale (AISRS). Of 226 patients who entered the 7-week trial, 110 were randomized to methylphenidate hydrochloride extended-release tablets and 116 were randomized to placebo. Treatment was initiated at 36 mg/day and patients continued with incremental increases of 18 mg/day (36 to 108 mg/day) based on meeting specific improvement criteria with acceptable tolerability. At the final study visit, mean change scores (LS Mean, SEM) for the investigator rating on the AISRS demonstrated that methylphenidate hydrochloride extended-release tablets was statistically significantly superior to placebo. </paragraph>
                        <paragraph>Study 6 was a multicenter, double-blind, randomized, placebo-controlled, parallel-group, dose-response study (5-week duration) with 3 fixed-dose groups (18, 36, and 72 mg). Patients were randomized to receive methylphenidate hydrochloride extended-release tablets administered at doses of 18 mg (n=101), 36 mg (n=102), 72 mg/day (n=102), or placebo (n=96). All three doses of methylphenidate hydrochlorideÂ extended-releaseÂ tablets were statistically significantly more effective than placebo in improving CAARS (Connersâ Adult ADHD Rating Scale) total scores at double-blind end point in adult subjects with ADHD.</paragraph>
                     </text>
                     <effectiveTime value="20240402"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_113655e6-145b-45f1-8b7e-b619533cc3d0">
               <id root="d137b725-350b-46af-857f-08961c4ccf8b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Methylphenidate hydrochloride extended-release tablets, USP are available as follows:</paragraph>
                  <paragraph>18 mg â Each yellow, film-coated, capsule shaped tablet imprinted with the Andrx logo and 725 on one side and plain on the other side contains 18 mg methylphenidate hydrochloride, USP. Tablets are supplied in bottles of 100 (NDC 62037-725-01).</paragraph>
                  <paragraph>27 mg â Each gray, film-coated, capsule shaped tablet imprinted with the Andrx logo and 734 on one side and plain on the other side contains 27 mg methylphenidate hydrochloride, USP. Tablets are supplied in bottles of 100 (NDC 62037-734-01).</paragraph>
                  <paragraph>36 mg â Each white, film-coated, capsule shaped tablet imprinted with the Andrx logo and 726 on one side and plain on the other side contains 36 mg methylphenidate hydrochloride, USP. Tablets are supplied in bottles of 100 (NDC 62037-726-01).</paragraph>
                  <paragraph>54 mg â Each red brown, film-coated, capsule shaped tablet imprinted with the Andrx logo and 727 on one side and plain on the other side contains 54 mg methylphenidate hydrochloride, USP. Tablets are supplied in bottles of 100 (NDC 62037-727-01).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage and Handling</content>
                  </paragraph>
                  <paragraph>Store at 20Â° to 25Â°C (68Â° to 77Â°F); excursions permitted to 15Â° to 30Â°C (59Â° to 86Â°F) [See USP Controlled Room Temperature]. Protect from humidity.</paragraph>
                  <paragraph>Dispense in tight, light-resistant container as defined in USP, with a child-resistant closure (as required).</paragraph>
               </text>
               <effectiveTime value="20240402"/>
            </section>
         </component>
         <component>
            <section ID="LINK_829fb2dd-301c-42bd-9162-8a069c60d4d2">
               <id root="f5e023fd-6bd1-482a-a72c-67c092984bbe"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Medication Guide).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Abuse, Misuse, and Addiction</content>
                  </paragraph>
                  <paragraph>Educate patients and their families about the risks of abuse, misuse, and addiction of methylphenidate hydrochloride extended-release tablets, which can lead to overdose and death, and proper disposal of any unused drug <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_c96903a8-8e52-464d-a214-e605a9c8a3ab">5.1</linkHtml>), Drug Abuse and Dependence (<linkHtml href="#LINK_2de45e7d-f3d8-47ab-8e03-328793cd40b6">9.2</linkHtml>), Overdosage (<linkHtml href="#LINK_43ad3db4-fc84-43bd-beaf-5b425909e046">10</linkHtml>)]. </content>Advise patients to store methylphenidate hydrochloride extended-release tablets in a safe place, preferably locked, and instruct patients to not give methylphenidate hydrochloride extended-release tablets to anyone else.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risks to Patients with Serious Cardiac Disease</content>
                  </paragraph>
                  <paragraph>Advise patients that there are potential risks to patients with serious cardiac disease, including sudden death, with methylphenidate hydrochloride extended-release tablets use. Instruct patients to contact a healthcare provider immediately if they develop symptoms such as exertional chest pain, unexplained syncope, or other symptoms suggestive of cardiac disease <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_460678ae-8587-4f7e-a306-b19eb4b4bd67">5.2</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Blood Pressure and Heart Rate</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride extended-release tablets can cause elevations in blood pressure and heart rate<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#LINK_b92519ff-9458-421f-81b3-fca364a4324a">5.3</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Psychiatric Risks</content>
                  </paragraph>
                  <paragraph>Advise patients that methylphenidate hydrochloride extended-release tablets, at recommended doses, can cause psychotic or manic symptoms, even in patients without a prior history of psychotic symptoms or mania <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_a28c27a6-3d0e-4f69-ab45-c0027b8ab91f">5.4</linkHtml>)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Priapism</content>
                  </paragraph>
                  <paragraph>Advise patients, caregivers, and family members of the possibility of painful or prolonged penile erections (priapism). <content styleCode="bold">Instruct the patient to seek immediate medical attention in the event of priapismÂ </content>
                     <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_d388e15d-cc41-40cc-8a5c-c38d753b1d61">5.6</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Circulation Problems in Fingers and Toes [Peripheral Vasculopathy, including Raynaudâs Phenomenon]</content>
                  </paragraph>
                  <paragraph>Instruct patients beginning treatment with methylphenidate hydrochloride extended-release tablets about the risk of peripheral vasculopathy, including Raynaudâs phenomenon, and associated signs and symptoms: fingers or toes may feel numb, cool, painful, and/or may change color from pale, to blue, to red.</paragraph>
                  <paragraph>Instruct patients to report to their physician any new numbness, pain, skin color change, or sensitivity to temperature in fingers or toes.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Instruct patients to call their physician immediately with any signs of unexplained wounds appearing on fingers or toes while taking methylphenidate hydrochloride extended-release tablets.</content>
                  </paragraph>
                  <paragraph>Further clinical evaluation (e.g., rheumatology referral) may be appropriate for certain patients.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Suppression of Growth</content>
                  </paragraph>
                  <paragraph>Advise patients, caregivers, and family members that methylphenidate hydrochloride extended-release tablets may cause slowing of growth and weight loss <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_0ab0a071-a25b-48a1-8e57-b285bf2d93b3">5.8</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Increased Intraocular Pressure (IOP) and Glaucoma</content>
                  </paragraph>
                  <paragraph>Advise patients that IOP and glaucoma may occur during treatment with methylphenidate hydrochloride extended-release tablets <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b669de13-880c-40bc-992e-0f9f4362dbc8">5.12</linkHtml>)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Motor and Verbal Tics, and Worsening of Touretteâs Syndrome</content>
                  </paragraph>
                  <paragraph>Advise patients that motor and verbal tics and worsening of Touretteâs Syndrome may occur during treatment with methylphenidate hydrochloride extended-release tablets. Instruct patients to notify their healthcare provider if emergence of new tics or worsening of tics or Touretteâs syndrome occurs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_7c983bbc-d11f-4eb0-b4eb-87a95bd9e3f5">5.13</linkHtml>)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Administration Instructions</content>
                  </paragraph>
                  <paragraph> Patients should be informed that methylphenidate hydrochloride extended-release tablets should be swallowed whole with the aid of liquids. Tablets should not be chewed, divided, or crushed. The medication is contained within a nonabsorbable shell designed to release the drug at a controlled rate. The tablet shell, along with insoluble core components, is eliminated from the body; patients should not be concerned if they occasionally notice in their stool something that looks like a tablet.</paragraph>
                  <paragraph>For more information call Teva at 1-888-838-2872.</paragraph>
                  <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                  <paragraph>Manufactured For:</paragraph>
                  <paragraph>
                     <content styleCode="bold">Teva Pharmaceuticals </content>
                  </paragraph>
                  <paragraph>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. C 4/2024</paragraph>
               </text>
               <effectiveTime value="20240402"/>
            </section>
         </component>
         <component>
            <section ID="LINK_248e4143-28e1-4a75-8af0-d1cb07752c98">
               <id root="4fdd7a19-7bda-479f-bd3a-a4ff6ee493f7"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                  <table width="814.333px">
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <content styleCode="bold">MEDICATION GUIDE</content>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate Hydrochloride </content>
                                 <content styleCode="bold">(meth" il fen' i date hye" droe klor' ide)</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Â </content>
                                 <content styleCode="bold">Extended-Release TabletsÂ  CII</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">What is the most important information I should know about methylphenidate hydrochloride extended-release tablets?</content>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride extended-release tablets may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Abuse, misuse, and addiction.</content> Methylphenidate hydrochloride extended-release tablets has a high chance for abuse and misuse and may lead to substance use problems, including addiction. Misuse and abuse of methylphenidate hydrochloride extended-release tablets, other methylphenidate containing medicines, and amphetamine containing medicines, can lead to overdose and death. The risk of overdose and death is increased with higher doses of methylphenidate hydrochloride extended-release tablets or when it is used in ways that are not approved, such as snorting or injection.</item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>Your healthcare provider should check you or your childâs risk for abuse, misuse, and addiction before starting treatment with methylphenidate hydrochloride extended-release tablets and will monitor you or your child during treatment.</item>
                                 <item>Methylphenidate hydrochloride extended-release tablets may lead to physical dependence after prolonged use, even if taken as directed by your healthcare provider.</item>
                                 <item>Do not give methylphenidate hydrochloride extended-release tablets to anyone else. See â<content styleCode="bold">What is methylphenidate hydrochloride extended-release tablets?â</content> for more information.</item>
                                 <item>Keep methylphenidate hydrochloride extended-release tablets in a safe place and properly dispose of any unused medicine. See <content styleCode="bold">âHow should I store methylphenidate hydrochloride extended-release tablets?â</content> for more information.</item>
                                 <item>Tell your healthcare provider if you or your child have ever abused or been dependent on alcohol, prescription medicines, or street drugs.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Risks for people with serious heart disease.</content> Sudden death has happened in people who have heart defects or other serious heart disease.</item>
                              </list>
                              <paragraph>Your healthcare provider should check you or your child carefully for heart problems before starting treatment with methylphenidate hydrochloride extended-release tablets. Tell your healthcare provider if you or your child have any heart problems, heart disease, or heart defects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider or go to the nearest hospital emergency room right away if you or your child have any signs of heart problems such as chest pain, shortness of breath, or fainting during treatment with methylphenidate hydrochloride extended-release tablets.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Increased blood pressure and heart rate.</content>
                                 </item>
                              </list>
                              <paragraph>Your healthcare provider should check your or your childâs blood pressure and heart rate regularly during treatment with methylphenidate hydrochloride extended-release tablets.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Mental (psychiatric) problems, including:</content>
                                 </item>
                              </list>
                              <list listType="unordered" styleCode="Circle">
                                 <item>new or worse behavior or thought problems</item>
                                 <item>new or worse bipolar illness</item>
                                 <item>new psychotic symptoms (such as hearing voices, or seeing or believing things that are not real) or new manic symptoms</item>
                              </list>
                              <paragraph>Tell your healthcare provider about any mental problems you or your child have, or about a family history of suicide, bipolar illness, or depression.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any new or worsening mental symptoms or problems during treatment with methylphenidate hydrochloride extended-release tablets, especially hearing voices, seeing or believing things that are not real, or new manic symptoms.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">What are methylphenidate hydrochloride extended-release tablets?</content>
                              <paragraph>Methylphenidate hydrochloride extended-release tablets are a central nervous system stimulant prescription medicine used for the treatment of Attention Deficit and Hyperactivity Disorder (ADHD) in children 6 years of age and older and adults up to 65 years of age. Methylphenidate hydrochloride extended-release tablets may help increase attention and decrease impulsiveness and hyperactivity in people with ADHD. It is not known if methylphenidate hydrochloride extended-release tablets are safe and effective in children under 6 years of age. Methylphenidate hydrochloride extended-release tablets has not been studied in adults older than 65 years of age. </paragraph>
                              <content styleCode="bold">Methylphenidate hydrochloride extended-release tablets are federally controlled substance (CII) because it contains methylphenidate that can be a target for people who abuse prescription medicines or street drugs</content>. Keep methylphenidate hydrochloride extended-release tablets in a safe place to protect it from theft. Never give your methylphenidate hydrochloride extended-release tablets to anyone else because it may cause death or harm them. Selling or giving away methylphenidate hydrochloride extended-release tablets may harm others and is against the law.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">Do not take methylphenidate hydrochloride extended-release tablets if you or your child:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are allergic to methylphenidate or any of the ingredients in methylphenidate hydrochloride extended-release tablets. See the end of this Medication Guide for a complete list of ingredients in methylphenidate hydrochloride extended-release tablets.</item>
                              </list>
                              <list listType="unordered" styleCode="Disk">
                                 <item> are taking, or have stopped taking within the past 14 days, a medicine called monoamine oxidase inhibitor (MAOI)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">Before taking methylphenidate hydrochloride extended-release tablets, tell your healthcare provider about all of your or your childâs medical conditions, including if you or your child:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have heart problems, heart disease, heart defects, or high blood pressure</item>
                                 <item>have mental problems including psychosis, mania, bipolar illness, or depression, or have a family history of suicide, bipolar illness, or depression</item>
                                 <item>have or have had seizures or have had an abnormal brain wave test (EEG)</item>
                                 <item>have circulation problems in fingers and toes</item>
                                 <item>have had a blockage or narrowing of the intestines</item>
                                 <item>have eye problems, including increased pressure in your eye, glaucoma, or problems with your close-up vision (farsightedness)</item>
                                 <item>have or had repeated movements or sounds (tics) or Touretteâs syndrome, or have a family history of tics or Touretteâs syndrome</item>
                                 <item>are pregnant or plan to become pregnant. It is not known if methylphenidate hydrochloride extended-release tablets will harm the unborn baby.</item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if methylphenidate hydrochloride extended-release tablets passes into the breastmilk. Talk to your healthcare provider about the best way to feed the baby during treatment with methylphenidate hydrochloride extended-release tablets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your healthcare provider about all of the medicines that you or your child take, </content>including prescription and over-the-counter medicines, vitamins, and herbal supplements.</paragraph>
                              <paragraph>Methylphenidate hydrochloride extended-release tablets and some medicines may interact with each other and cause serious side effects. Sometimes the doses of other medicines will need to be changed during treatment with methylphenidate hydrochloride extended-release tablets. Your healthcare provider will decide whether methylphenidate hydrochloride extended-release tablets can be taken with other medicines.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your healthcare provider if you or your child take:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>a medicine to treat blood pressure</item>
                                 <item>coumarin anticoagulants (a medicine that prevent blood clots, such as warfarin)</item>
                                 <item>a medicine to treat seizures</item>
                                 <item>a medicine to treat depression</item>
                                 <item>risperidone</item>
                              </list>
                              <paragraph>Know the medicines that you or your child take. Keep a list of your or your childâs medicines with you to show your healthcare provider and pharmacist when you or your child get a new medicine.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not start any new medicine during treatment with methylphenidate hydrochloride extended-release tablets without first talking to your healthcare provider.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">How should methylphenidate hydrochloride extended-release tablets be taken?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take methylphenidate hydrochloride extended-release tablets exactly as prescribed by your or your childâs healthcare provider.</item>
                                 <item>Your healthcare provider may change the dose or tell you to stop taking methylphenidate hydrochloride extended-release tablets if needed.</item>
                                 <item>Take methylphenidate hydrochloride extended-release tablets 1 time each day in the morning with or without food.</item>
                                 <item>Swallow methylphenidate hydrochloride extended-release tablets whole with water or other liquids. <content styleCode="bold">Do not chew, crush, or divide the tablets.</content> Tell your healthcare provider if you or your child cannot swallow methylphenidate hydrochloride extended-release tablets whole. A different medicine may need to be prescribed.</item>
                                 <item>Methylphenidate hydrochloride extended-release tablets does not dissolve completely in the body after all the medicine has been released. You or your child may sometimes notice the empty tablet in a bowel movement. This is normal.</item>
                                 <item>Your healthcare provider may do blood tests during treatment with methylphenidate hydrochloride extended-release tablets to check your or your childâs blood count. </item>
                              </list>
            If you or your child take too much methylphenidate hydrochloride extended-release tablets, call your healthcare provider or Poison Help line at 1-800-222-1222 or go to the nearest hospital emergency room right away.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Toprule Lrule Rrule">Â <content styleCode="bold">What are the possible side effects of methylphenidate hydrochloride extended-release tablets?</content>
                              <paragraph>
                                 <content styleCode="bold">Methylphenidate hydrochloride extended-release tablets may cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>See <content styleCode="bold">âWhat is the most important information I should know about methylphenidate hydrochloride extended-release tablets?â</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Seizures</content>. Your healthcare provider will stop treatment with methylphenidate hydrochloride extended-release tablets if you or your child have a seizure.</item>
                                 <item>
                                    <content styleCode="bold">Painful and prolonged erections (priapism).</content> Priapism that may require surgery has happened in people who take products that contain methylphenidate. <content styleCode="bold">If you or your child develop priapism, get medical help right away.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Circulation problems in fingers and toes (peripheral vasculopathy, including Raynaudâs phenomenon).</content>
                                 </item>
                              </list>
                              <paragraph>Signs and symptoms may include:</paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>fingers or toes may feel numb, cool, painful</item>
                                 <item>fingers or toes may change color from pale, to blue, to red</item>
                              </list>
                              <paragraph>Tell your healthcare provider if you or your child have any numbness, pain, skin color change, or sensitivity to</paragraph>
                              <paragraph>temperature in your fingers or toes.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Call your healthcare provider right away if you or your child have any signs of unexplained wounds appearing on fingers or toes during treatment with methylphenidate hydrochloride extended-release tablets.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Slowing of growth (height and weight) in children. </content>Children should have their height and weight checked often during treatment with methylphenidate hydrochloride extended-release tablets. Methylphenidate hydrochloride extended-release tablets treatment may be stopped if your child is not growing or gaining weight as expected.</item>
                                 <item>
                                    <content styleCode="bold">Eye problems (increased pressure in the eye and glaucoma). </content>Call your healthcare provider right away if you or your child develop changes in your vision or eye pain, swelling, or redness.</item>
                                 <item>
                                    <content styleCode="bold">New or worsening tics or worsening Touretteâs syndrome</content>. Tell your healthcare provider if you or your child get any new or worsening tics or worsening Touretteâs syndrome during treatment with methylphenidate hydrochloride extended-release tablets.</item>
                                 <item>
                                    <content styleCode="bold">Eyesight changes or blurred vision.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Possible blockage of the intestine</content>. Because the methylphenidate hydrochloride extended-release tablets tablet does not change in shape in the intestines (GI tract), methylphenidate hydrochloride extended-release tablets should not be taken by people with severe intestinal problems (preexisting severe gastrointestinal narrowing).</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">The most common side effect of methylphenidate hydrochloride extended-release tablets in children is </content>upper stomach-area (abdominal) pain.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">The most common side effects of methylphenidate hydrochloride extended-release tablets in adults include:</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Lrule">Â 
            <list listType="unordered" styleCode="Disc">
                                 <item>decreased appetite</item>
                                 <item>headache</item>
                                 <item>dry mouth</item>
                                 <item>nausea </item>
                                 <item>trouble sleeping</item>
                              </list>
                           </td>
                           <td styleCode=" Rrule">Â 
            <list listType="unordered" styleCode="Disc">
                                 <item>anxiety</item>
                                 <item>dizziness</item>
                                 <item>weight loss</item>
                                 <item>irritability</item>
                                 <item>increased sweating</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Lrule Rrule">Â These are not all the possible side effects of methylphenidate hydrochloride extended-release tablets.
            <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</paragraph>
            You may also report side effects to Teva at 1-888-838-2872.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">How should I store methylphenidate hydrochloride extended-release tablets?</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store methylphenidate hydrochloride extended-release tablets at room temperature between 59Â° to 86Â°F (15Â° to 30Â°C).</item>
                                 <item>Protect from moisture.</item>
                                 <item>Store methylphenidate hydrochloride extended-release tablets in a safe place, like a locked cabinet.</item>
                                 <item>Dispose of remaining, unused, or expired methylphenidate hydrochloride extended-release tablets by a medicine take-back program at a U.S. Drug Enforcement Administration (DEA) authorized collection site. If no take-back program or DEA authorized collector is available, mix methylphenidate hydrochloride extended-release tablets with an undesirable, nontoxic substance such as dirt, cat litter, or used coffee grounds to make it less appealing to children and pets. Place the mixture in a container such as a sealed plastic bag and throw away methylphenidate hydrochloride extended-release tablets in the household trash. Visit www.fda.gov/drugdisposal for additional information on disposal of unused medicines.</item>
                              </list>
            Keep methylphenidate hydrochloride extended-release tablets and all medicines out of the reach of children.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">General information about the safe and effective use of methylphenidate hydrochloride extended-release tablets.</content>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use methylphenidate hydrochloride extended-release tablets for a condition for which it was not prescribed. Do not give methylphenidate hydrochloride extended-release tablets to other people, even if they have the same condition. It may harm them and it is against the law. </paragraph>
            You can ask your healthcare provider or pharmacist for information about methylphenidate hydrochloride extended-release tablets that is written for healthcare professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">Â <content styleCode="bold">What are the ingredients in methylphenidate hydrochloride extended-release tablets?</content>
                              <paragraph>
                                 <content styleCode="bold">Active ingredient: </content>methylphenidate hydrochloride</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Inactive ingredients:</content> colloidal silicon dioxide, fumaric acid, hypromellose 2208, hypromellose 2910, lactose monohydrate, magnesium stearate, methacrylic acid copolymer Type A, methacrylic acid copolymer Type B, talc, titanium dioxide, and triethyl citrate. The 18 mg strength also contains iron oxide red, iron oxide yellow, polyethylene glycol 3350, and polyvinyl alcohol. The 27 mg strength also contains FD&amp;C Blue #2/Indigo Carmine Aluminum Lake, iron oxide black, iron oxide yellow, polyethylene glycol 3350, and polyvinyl alcohol. The 36 mg strength also contains triacetin. The 54 mg strength also contains iron oxide red, polyethylene glycol 3350, and polyvinyl alcohol. The imprinting ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac.</paragraph>
                              <paragraph>Manufactured For: <content styleCode="bold">Teva Pharmaceuticals, </content>Parsippany, NJ 07054</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Rev. C 4/2024</paragraph>
               </text>
               <effectiveTime value="20240402"/>
            </section>
         </component>
         <component>
            <section ID="LINK_732f08a1-426a-43e1-950c-7bcec191c2c2">
               <id root="f4ed599e-df2b-4695-ae9f-0be5978da183"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 62037-725-01</paragraph>
                  <paragraph>Once-Daily</paragraph>
                  <paragraph>MethylphenidateÂ HydrochlorideÂ Extended-ReleaseÂ Tablets, USPÂ  Â CII</paragraph>
                  <paragraph>18 mgÂ  Â Â </paragraph>
                  <paragraph>PHARMACIST: Dispense the accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>new</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_21f5f0a6-41e1-4611-96a0-9dae33e8dc8b">
               <id root="b9a9880d-cfbf-4baf-9519-844cbf651f16"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 62037-734-01<br/>
                  </paragraph>
                  <paragraph>Once-Daily</paragraph>
                  <paragraph>MethylphenidateÂ HydrochlorideÂ Extended-ReleaseÂ Tablets, USPÂ  Â CII<br/> 27 mg</paragraph>
                  <paragraph>PHARMACIST: Dispense the accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM6"/>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <observationMedia ID="MM6">
                     <text>new</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_00e034e4-eea6-4b73-919e-206a4c838730">
               <id root="da5de903-1b3f-41e8-a299-512569903ed8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 62037-726-01</paragraph>
                  <paragraph>Once-Daily</paragraph>
                  <paragraph>MethylphenidateÂ HydrochlorideÂ Extended-ReleaseÂ Tablets, USPÂ  Â CII<br/>36 mg</paragraph>
                  <paragraph>PHARMACIST: Dispense the accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM7"/>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <observationMedia ID="MM7">
                     <text>new</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3529bb98-6488-4d83-8920-5bcdd43e26d6">
               <id root="6988e175-b3d3-4fbd-8d18-53601f9bef0f"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 62037-727-01</paragraph>
                  <paragraph>Once-Daily</paragraph>
                  <paragraph>MethylphenidateÂ HydrochlorideÂ Extended-ReleaseÂ Tablets, USPÂ  Â CII<br/> 54 mgÂ  Â Â </paragraph>
                  <paragraph>PHARMACIST: Dispense the accompanying Medication Guide to each patient.</paragraph>
                  <paragraph>Rx only</paragraph>
                  <paragraph>100 Tablets</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20240402"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>new</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>